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Brain-intrinsic degenerative cascades are a proposed factor driving inflammatory lesion formation in 32 
multiple sclerosis (MS) patients. We recently showed that encephalitogenic lymphocytes are recruited 33 
to the sites of active demyelination induced by cuprizone. Here, we investigated whether cuprizone-34 
induced oligodendrocyte and myelin pathology is sufficient to trigger peripheral immune cell 35 
recruitment into the forebrain. We show that early cuprizone-induced white matter lesions display a 36 
striking similarity to early MS lesions, i.e., oligodendrocyte degeneration, microglia activation and 37 
absence of severe lymphocyte infiltration. Such early cuprizone lesions are sufficient to trigger 38 
peripheral immune cell recruitment secondary to subsequent EAE (experimental autoimmune 39 
encephalomyelitis) induction. The lesions are characterized by discontinuation of the perivascular glia 40 
limitans, focal axonal damage, and perivascular astrocyte pathology. Time course studies showed that 41 
the severity of cuprizone-induced lesions positively correlates with the extent of peripheral immune cell 42 
recruitment. Furthermore, results of genome-wide array analyses suggest that moesin is integral for early 43 
microglia activation in cuprizone and MS lesions. This study underpins the significance of brain-44 
intrinsic degenerative cascades for immune cell recruitment and, in consequence, MS lesion formation.  45 
Keywords: Moesin, multiple sclerosis, cuprizone, experimental autoimmune encephalomyelitis  46 
 47 
Introduction 48 
Multiple sclerosis (MS) is a neuroinflammatory disorder of the central nervous system (CNS), 49 
potentially leading to severe motor, sensory, or visual deficits. Clinically, MS represents one of the main 50 
causes of disability in the young adult, and thus has a high socio-economic impact. At the 51 
histopathological level, MS lesions are characterized by oligodendrocyte death, demyelination, gliosis, 52 
axonal damage, and peripheral immune cell infiltration (Bauer, Rauschka et al. 2001, Benn, Halfpenny 53 
et al. 2001). Despite decades of research, it is still not clear what causes the formation of new 54 
inflammatory lesions in MS patients.  55 
MS can be, based on the disease course, clinically categorized into three groups: relapsing-remitting, 56 
secondary progressive, and primary progressive. In most patients, the initial course of the disease is 57 
relapsing-remitting which is characterized by acute clinical attacks that are followed by complete or 58 
incomplete recovery, and a period of remission in between the attacks. Many patients with an initial 59 
relapsing-remitting disease course develop secondary progressive MS. In these patients, a more or less 60 
continuous decline of neurological functioning occurs with or without occasional attacks (Lublin, 61 
Reingold et al. 2014). Primary progressive MS is characterized by the accumulation of clinical disability 62 
from the onset of symptoms, without early relapses or remissions. 63 
It is broadly accepted that the histopathological correlate of acute attacks is a focal inflammatory 64 
demyelinating white matter lesion. These focal inflammatory lesions impact on neuronal integrity 65 




1997, Kornek, Storch et al. 2000). Although the accumulation of peripheral immune cells is a 67 
characteristic of such lesions, it is not clear what triggers the influx of immune cells into the central 68 
nervous system (CNS). However, a degenerative process within the brain has been suggested as one 69 
potential trigger mechanism (De Groot, Bergers et al. 2001, Barnett and Prineas 2004, Scheld, Ruther 70 
et al. 2016, Ruther, Scheld et al. 2017). Indeed, that damage to the brain parenchyma can trigger the site 71 
of inflammatory lesion formation, is well known. In both - active immunization and passive transfer 72 
forms of experimental autoimmune encephalomyelitis (EAE) - an autoimmune animal model of MS, 73 
inflammatory lesions rapidly localize at sites of non-specific brain damage, including thermal brain 74 
injury (Levine and Hoenig 1968, Levine and Hoenig 1971), cyanide-induced encephalopathy (Levine 75 
1960), cortical cryolesions (Phillips, Weller et al. 1995, Lake, Weller et al. 1999), experimental 76 
induction of Wallerian degeneration (Konno, Yamamoto et al. 1990), or cytokine injection (Sun, 77 
Newman et al. 2004). In humans, it has been suggested that mechanical stresses can determine the site 78 
of spinal cord MS lesions (Oppenheimer 1978). These studies clearly illustrate the significance of brain-79 
intrinsic degenerative cascades for immune cell recruitment and MS lesion formation. 80 
We recently demonstrated that cuprizone-induced demyelination can trigger peripheral immune cell 81 
recruitment into the forebrain after MOG35-55 immunization (Scheld, Ruther et al. 2016, Ruther, Scheld 82 
et al. 2017). In these studies, demyelination of the murine forebrains was induced by a 3-weeks 83 
cuprizone (Cup) intoxication protocol, followed by two weeks on normal chow. At week five, 84 
encephalitogenic T cells in peripheral lymphoid organs were generated by active immunization with the 85 
myelin oligodendrocyte glycoprotein 35–55 peptide (MOG35–55) (Iglesias, Bauer et al. 2001). While 86 
peripheral immune cell recruitment was minimal in the forebrains of MOG35–55-immunized mice (i.e., 87 
active EAE induction), cuprizone-induced demyelination revealed to be a potent trigger for the 88 
recruitment of monocytes, lymphocytes and granulocytes (Scheld, Ruther et al. 2016, Ruther, Scheld et 89 
al. 2017). A drawback of these previous studies using this so-called Cup/EAE model is, however, that 90 
active MOG35–55 immunization was induced at a time when demyelination was already fully established. 91 
This is in contrast to proposed mechanisms operant during early MS lesion formation, i.e., 92 
oligodendrocyte degeneration and microglial activation associated with few lymphocytes and 93 
phagocytes in regions of relative myelin preservation (van der Valk and De Groot 2000, De Groot, 94 
Bergers et al. 2001, Barnett and Prineas 2004, Marik, Felts et al. 2007). 95 
The purpose of this study was, therefore, to investigate whether a short-term cuprizone intoxication 96 
protocol is sufficient to trigger peripheral immune cell recruitment after MOG35-55 immunization. 97 
Additionally, by using gene array technology, we aimed at identifying factors orchestrating immune cell 98 
recruitment into the forebrains of Cup/EAE mice. We can show that cuprizone-induced oligodendrocyte 99 
degeneration with concomitant microglia activation is sufficient to trigger the recruitment of peripheral 100 
immune cells into the forebrain. Of note, the extent of cuprizone-induced tissue injury positively 101 




array analyses and immunohistochemical stains suggest an important role of moesin+ microglia for the 103 
formation of the inflammatory foci. 104 
 105 
Materials and Methods 106 
Animals and experimental groups 107 
8 week-old C57BL/6 female mice (19 g - 20 g) were purchased from Janvier Labs (Le Genest-Saint-108 
Isle, France). Microbiological monitoring was performed according to the Federation of European 109 
Laboratory Animal Science Associations recommendations. A maximum of five animals were housed 110 
per cage (cage area 435 cm2). Animals were kept under standard laboratory conditions (13 h light/11 h 111 
dark cycle, controlled temperature 22 °C ± 2 °C and 50 % ± 10 % humidity) with access to food and 112 
water ad libitum. It was assured that researchers and technicians did not use any light during the night 113 
cycle period. Nestlets were used for environmental enrichment. All experiments were formally approved 114 
by the Regierung Oberbayern (reference number 55.2-154-2532-73-15). Mice were randomly assigned 115 
to the following groups (see figure 3A): (A) control, animals received a diet of standard rodent chow 116 
for the duration of the study; (B) 1wk cuprizone (Cup) /EAE, animals were fed a diet containing 0.25% 117 
cuprizone (bis(cyclohexanone)oxaldihydrazone; Sigma-Aldrich, Taufkirchen, Germany) mixed into 118 
ground standard rodent chow for one week, followed by normal chow for 24 h, and were then immunized 119 
with MOG35–55 (Hooke Laboratories, Inc., Lawrence, USA) at the beginning of week two; (C) 3wks 120 
cup/EAE, animals were fed the cuprizone diet for three weeks, and were then immunized with MOG35–121 
55 at the beginning of week four; (D) 3 cup+2wks normal chow/EAE, mice were fed the cuprizone diet 122 
for the first three weeks and were then immunized with MOG35–55 at the beginning of week six. 123 
Additional animals were fed the cuprizone diet for either 1wk, 3wks, or 5wks and 3 wks+2wks normal 124 
chow without any additional MOG35-55 immunization (not shown in figure 3A). This experimental setup 125 
was published previously (Scheld, Ruther et al. 2016, Ruther, Scheld et al. 2017).  126 
 127 
Multiple sclerosis tissues 128 
Paraffin-embedded postmortem brain tissues were obtained through a rapid autopsy protocol from 129 
subjects with mainly progressive MS (in collaboration with the Netherlands Brain Bank, Amsterdam). 130 
The study was approved by the institutional ethics review board, and all donors or their relatives 131 
provided written consent for the use of brain tissues and clinical information for research purposes. 132 
Staging of lesions was performed as reported previously (van der Valk and De Groot 2000, Grosse-133 
Veldmann, Becker et al. 2016, Trepanier, Hildebrand et al. 2018). In brief, active lesions are defined as 134 
hypercellular throughout the entire lesion, chronic active lesions are defined as a lesion with a 135 
hypocellular center and a hypercellular rim, and chronic inactive lesions are defined as hypocellular 136 
throughout the entire lesion. For the study, three chronic active and three chronic inactive lesions were 137 




delay in hours was 10.02 ± 0.3365. Staging of the white matter lesion activity was performed using anti-139 
PLP and anti-MHC class II (LN3)-stained sections. 140 
 141 
EAE and disease scoring 142 
To induce the formation of encephalitogenic T cells in peripheral lymphatic tissues, mice were 143 
subcutaneously immunized with an emulsion of MOG35–55 peptide dissolved in complete Freund’s 144 
adjuvant followed by intraperitoneal injections of pertussis toxin in PBS (PTX) on the day of and the 145 
day after immunization (Hooke Laboratories, Inc., Lawrence, USA) as published previously (Ruther, 146 
Scheld et al. 2017). Disease severity was scored as follows: 1, the entire tail drops over the observer’s 147 
finger when the mouse is picked up by base of the tail; 2, the legs are not spread apart but held close 148 
together when the mouse is picked up by base of the tail, and mice exhibit a clearly apparent wobbly 149 
gait; 3, the tail is limp and mice show complete paralysis of hind legs (a score of 3.5 is given if the 150 
mouse is unable to raise itself when placed on its side); 4, the tail is limp and mice show complete hind 151 
leg and partial front leg paralysis, and the mouse is minimally moving around the cage but appears alert 152 
and feeding (a score of 4 was not attained by any of the mice in our study).  153 
 154 
Tissue preparation 155 
For histological and immunohistochemical studies, mice were anaesthetized with ketamine (100 156 
mg·kg−1 i.p.) and xylazine (10 mg·kg−1 i.p.), and transcardially perfused with ice-cold PBS followed by 157 
a 3.7% formaldehyde solution (pH 7.4). Brains were postfixed overnight in a 3.7% formaldehyde 158 
solution, dissected, embedded in paraffin, and then coronal sections (5 μm) were prepared (Acs, Kipp 159 
et al. 2009, Clarner, Diederichs et al. 2012). Spinal cords were incubated in a Na/EDTA 160 
(ethylenediaminetetraacetic acid) solution for 48 h (changed once after ~24h) at 37C prior to paraffin 161 
embedding. For gene expression studies, tissues were manually dissected after transcardial PBS 162 
perfusion, immediately frozen in liquid nitrogen, and kept at -80C until further processing.  163 
 164 
Immunohistochemistry/Histochemistry and Evaluation 165 
For immunohistochemistry, sections were rehydrated and, if necessary, antigens were unmasked by 166 
heating in Tris/EDTA (pH 9.0) or citrate (pH 6.0) buffer. After washing in PBS, sections were blocked 167 
in blocking solution (serum of the species in which the secondary antibody was produced) for 1 h. Then, 168 
sections were incubated overnight (4 C) with primary antibodies diluted in blocking solution. The next 169 
day, slides were incubated in 0.3% hydrogen peroxide/PBS for 1 h and then incubated with biotinylated 170 
secondary antibodies for 1 h followed by peroxidase-coupled avidin-biotin complex (ABC kit; Vector 171 
Laboratories, Peterborough, UK). Sections were finally exposed to 3,3-diaminobenzidine (DAKO, 172 
Santa Clara, CA, USA) as a peroxidase substrate as published previously (Hoflich, Beyer et al. 2016). 173 
To visualize cell nuclei, sections were stained with hematoxylin solution. Negative control sections 174 




staining. Antibodies used in this study are listed in supplementary table 1. Luxol fast blue 176 
(LFB)/periodic acid-Schiff (PAS) stains were performed following standard protocols.  177 
Stained and processed sections were digitalized using a Nikon ECLIPSE 50i microscope (Nikon, Nikon 178 
Instruments, Düsseldorf, Germany) equipped with a DS-2Mv camera. The open source program ImageJ 179 
(NIH, Bethesda, MD, USA) was used to determine staining intensities, cellular densities and to quantify 180 
the densities of APP+ spheroids at specified distances from inflamed vessels (0-100 µm). To evaluate 181 
staining intensity using semi-automated densitometrical evaluation after threshold-setting, acquired 182 
images were converted to grey scale images, and a global thresholding algorithm was used for dividing 183 
each image into two classes of pixels (black and white; i.e., binary conversion). Global thresholding 184 
works by choosing a value cutoff, such that every pixel less than that value is considered one class, 185 
while every pixel greater than that value is considered the other class. Relative staining intensity was 186 
then quantified in binary converted images, and results are presented as percentage area. To quantify the 187 
numbers and localization of perivascular cuffs (PVCs) per section in the forebrain, lesions were 188 
identified in hematoxylin and eosin (H&E)-stained sections by one evaluator blinded to the treatment 189 
groups, and the results were averaged per brain section. Forebrains were analyzed between the levels 190 
R215 and R295 according to the mouse brain atlas by Sidman et al. 191 
(http://www.hms.harvard.edu/research /brain/atlas.html) as published previously (Ruther, Scheld et al. 192 
2017). For the analysis of IBA1+ and CD3+ cell densities in mice brains, and moesin+ cell densities in 193 
human MS lesions, stained sections were scanned with the Zeiss Mirax Midi scanner (Zeiss, Carl Zeiss 194 
MicroImaging GmbH, Jena, Germany) equipped with a Stingray camera, and analyzed with the open 195 
source program ViewPoint Online (PreciPoint, Freising, Germany).  196 
 197 
Immunofluorescence labeling 198 
For immunofluorescence labelling, sections were deparaffinized, rehydrated, unmasked, and blocked in 199 
serum of the species in which the secondary antibody was raised. Sections were incubated overnight (4 200 
C) with the indicated combination of primary antibodies diluted in blocking solution. For double-201 
labelling experiments, anti-moesin antibodies were either combined with goat anti-IBA1 for the 202 
detection of murine microglia, or anti-MHC-II (LN3) for the detection of activated microglia and 203 
monocytes in human tissues. Acute axonal injury was visualized with anti-amyloid precursor protein 204 
(APP) antibodies. After extensive washing, sections were incubated with a combination of fluorescent 205 
secondary antibodies. Sections were then incubated with Hoechst 33258 (bisBenzimide H 33258 Sigma 206 
Aldrich, Steinheim, Germany; 1:10,000) diluted in PBS for the staining of cell nuclei. To exclude 207 
unspecific binding of the fluorescent secondary antibodies to primary antibodies, negative controls were 208 
performed by first incubating sections with the primary antibodies and subsequently incubating these 209 
sections with the “wrong” secondary antibodies. Unspecific secondary antibody binding was excluded 210 
by incubating sections with the fluorescent secondary antibodies alone. Stained and processed sections 211 




Transmission electron microscopy 213 
For ultrastructural studies, tissue samples were fixed in 2.5% glutaraldehyde (Science Services, Munich, 214 
Germany) cacodylate buffer (pH 7.4; Merck-Millipore, Darmstadt, Germany) at 4 C overnight as 215 
described previously (Noell, Wolburg-Buchholz et al. 2012). Thereafter, samples were embedded in 216 
Araldite (Serva, Heidelberg, Germany), and ultrathin sections were cut using a Leica ultramicrotome 217 
(Leica, Wetzlar, Germany) and analyzed using a Zeiss EM-10 transmission electron microscope (Zeiss, 218 
Oberkochen, Germany). 219 
 220 
Gene array analyses 221 
Genome-wide gene expression of corpus callosum (CC) from control mice and mice fed with cuprizone 222 
(male) for 1 week was analyzed in independent quadruplicates using Affymetrix GeneChip® 223 
MouseGene1.0 ST Arrays. Total RNA was isolated using RNeasy Kits from QIAGEN, and quantity 224 
was assessed using the NanoDrop-1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, 225 
U.S.A.) and RNA quality was assessed using the RNA 6000 NanoChips with the Agilent 2100 226 
Bioanalyzer (Agilent, Waldbronn, Germany). Total RNA samples, each 150 ng, were prepared for the 227 
GeneChip® Mouse Gene 1.0 ST Arrays (Affymetrix, USA), and hybridized to the arrays according to 228 
the Ambion whole transcript expression and the Affymetrix whole transcript terminal labelling and 229 
control kits manuals. Processed samples were hybridized to the GeneChip® Mouse Gene 1.0 ST Arrays 230 
at 45°C for 16h with 60rpms, washed and stained on a Fluidics Station 450 (program FS450_00007) 231 
and scanned on GeneChip® Scanner 3000 7G (both Affymetrix). Raw image data were analyzed with 232 
Affymetrix® Expressin ConsoleTM Software, gene expression intensities were normalized and 233 
summarized with robust multiarray average algorithm (Irizarry, Hobbs et al. 2003). To identify genes 234 
differentially expressed between cuprizone treated and control mice a comparison analysis using 235 
Affymetrix Transcriptome Analysis Console (TAC) 4.0 Software was performed. Gene expression was 236 
considered as changed if transcript levels between cuprizone treated and control groups were differential 237 
with a 1.5-fold change and a FDR p value of < 0.05. Gene ontology enrichment analysis was performed 238 
using the “Enrichment analysis” tool (http://www.geneontology.org). The following items were applied: 239 
‘GO biological process’ for annotation data set, ‘Fischer’s exact” for test-type, and Bonferroni 240 
correction for multiple testing. A list of up- and down regulated genes is provided in supplementary 241 
table 2. The microarray data have additionally been deposited in the Gene Expression Omnibus database 242 
#GSE119672. 243 
 244 
Statistical analyses 245 
Statistical analyses were performed using Prism 5 (GraphPad Software Inc., San Diego, CA, USA). All 246 
data are given as arithmetic means ± SEMs. A p value of <0.05 was considered to be statistically 247 
significant. Applied statistical tests are given in the respective figure legends. No outliers were excluded 248 





Histopathological characteristics of initial demyelinating MS lesions are (i) stressed oligodendrocytes 251 
with apoptotic-like nuclear changes, (ii) activated microglia, dispersed between seemingly intact myelin, 252 
and (iii) few if any lymphocytes (Barnett and Prineas 2004, Marik, Felts et al. 2007, Haider, Fischer et 253 
al. 2011, Prineas and Parratt 2012). In a first step, we investigated histopathological characteristics of 254 
early cuprizone lesions. Numerous apoptotic oligodendrocytes (i.e., condensed and/or fragmented nuclei 255 
of cells in a chain-like formation in H&E-stained sections, see arrows in figure 1A) were observed in 256 
the CC of animals treated with cuprizone for one week. Apoptotic cells were absent in control animals. 257 
In both the cortex and the CC, numerous ATF3+ cells were observed in cuprizone-intoxicated but not 258 
control animals (figure 1B), showing activation of a stress response in oligodendrocytes (Goldberg, 259 
Daniel et al. 2013). Immunohistochemical stains for three distinct myelin proteins, namely proteolipid 260 
protein (PLP), myelin-associated glycoprotein (MAG), and 2',3'-cyclic nucleotide 3' phosphodiesterase 261 
(CNPase), as well as the histochemical stain Luxol Fast Blue/Periodic acid-Schiff (LFB/PAS) 262 
demonstrated the absence of demyelination at week 1 (figures 1C-F), but severe demyelination after a 263 
5 weeks continuous cuprizone intoxication period. The presence of intact myelin was also evident on 264 
the ultrastructural level (figure 1J) and verified in anti-myelin protein stained sections by unbiased 265 
densitometrical analyses (figure 1K). While anti-myelin staining intensities were unchanged after 1 and 266 
3 weeks continuous cuprizone-intoxication, severe anti-PLP, anti-MAG and anti-CNPase staining 267 
intensities were observed after 5 weeks continuous cuprizone-intoxication. Anti-ionized calcium-268 
binding molecule 1 (IBA1) staining of control brain sections showed cells with a small cell body and 269 
thin, highly ramified cell processes, both characteristics of resting microglia. After 1 week cuprizone 270 
exposure, cell processes were swollen and less ramified whereas cell bodies showed hypertrophy, 271 
indicating an activated microglia phenotype (figure 1G). Furthermore, densities of anti-IBA1+ cells were 272 
significantly higher after 1 week of cuprizone intoxication (control: 83.7±11.4 versus 319.6±52.6 273 
cells/mm2, p≤0.05). CD3+ and CD4+ lymphocytes were virtually absent in control (0.0±0.0 CD3+ 274 
cells/mm2; n=5) and 1 week (3.7±1.5 CD3+ cells/mm2; n= 5) cuprizone-intoxicated animals (figures 275 
1H/I). In summary, the histopathological characteristics of the initial demyelinating lesions in MS are 276 
well reproduced in mice following a one week cuprizone intoxication protocol.  277 
Next, we investigated whether the observed histopathological changes are sufficient to trigger peripheral 278 
immune cell recruitment into the forebrain after MOG35-55 immunization. To this end, a second cohort 279 
of animals was intoxicated with cuprizone for one week and subsequently immunized with MOG35-55 280 
peptide (group B in figure 3A). A previous study reported that cuprizone intoxication in mice halts T 281 
cell mediated autoimmunity (Mana, Fordham et al. 2009). We, thus investigated whether the severity of 282 
clinical symptoms in classical MOG35-55-immunized EAE mice was comparable in animals with or 283 
without previous cuprizone intoxication. Consequently, clinical scores were daily recorded and 284 




observed for the EAE parameters disease onset (EAE, 12.2 ± 0.3742 vs 1wk Cup/EAE, 10.8 ± 0.4899 d 286 
after immunization; p = 0.06) and maximum disease score (EAE, 2.7 ± 0.4673 vs 1 wk Cup/EAE, 2.5 ± 287 
0.4183; p = 0.76) (figures 2 A).  288 
In a next step, we analyzed the forebrains of treated mice at distinct rostral-to-caudal levels for the 289 
presence and localization of PVCs, a hallmark of active MS lesions (Maggi, Macri et al. 2014). This 290 
analysis was performed at the level of the anterior commissure (i.e., R215-235), the ventral hippocampal 291 
commissure (i.e., R245-265) and the rostral hippocampus (i.e., R275-295), respectively. As shown in 292 
figures 2B/C, PVCs were virtually absent in the forebrains of control mice. Some infiltrates were found 293 
in the forebrains of MOG35-55-immunized animals, and these were located predominantly around the 294 
third ventricle. In contrast, the forebrains of 1wk Cup/EAE animals contained a significant number of 295 
PVCs. Such infiltrates were widespread within the forebrain, including the cortex, CC, and subcortical 296 
regions. 297 
Next, we examined whether the severity of cuprizone-induced injury (i.e., oligodendrocyte degeneration 298 
and microglia activation) correlates with the extent of peripheral immune cell recruitment. To investigate 299 
this aspect, two separate cohorts of animals were treated cuprizone for one or three weeks. A third cohort 300 
of animals was treated cuprizone for three weeks, followed by two weeks on normal chow (i.e., 3 weeks 301 
cuprizone + 2 weeks normal chow; 3+2) as published previously (see figure 3A) (Scheld, Ruther et al. 302 
2016, Ruther, Scheld et al. 2017). First, we investigated myelination and microglia activation before the 303 
MOG35-55 immunization (see arrows in figure 3A which illustrates the time point of this analysis). As 304 
shown in figure 3B, demyelination (PLP and LFB/PAS) of the corpus callosum was absent in 1 week, 305 
moderate in 3 weeks, but severe in 3+2 weeks intoxicated animals, respectively. Concomitant to the 306 
extent of demyelination, microgliosis (IBA1) was moderate at 1 week, intermediate at week 3, and 307 
severe in 3+2 weeks intoxicated animals. Next, additional animals were immunized with MOG35-55 308 
peptide after week 1, 3 or 3+2 cuprizone, and numbers of PVCs were quantified two weeks after the 309 
immunization with the MOG35-55 peptide. As demonstrated in figure 3C, the greater the extent of 310 
cuprizone-induced metabolic injury, the higher the number of PVCs. Numbers of PVCs per brain section 311 
were low in 1 week cup/EAE, intermediate in 3 weeks cup/EAE, and high in 3+2 weeks normal 312 
chow/EAE mice.  313 
The resultant inflammatory foci were subsequently characterized at the level of the anterior commissure 314 
(i.e., R215) in the 1wk Cup/EAE animals. As shown in figure 4, these focal inflammatory infiltrates are 315 
characterized by perivascular immune cell accumulation (i.e., within an enlarged Virchow-Robin space; 316 
figures 4A/A’;H&E), perivascular microgliosis/infiltrating macrophages (figures 4B/B’; IBA1), and 317 
moderate demyelination (figures 4C/C’; LFB/PAS). Double staining experiments for CD3 (green) and 318 
GFAP (red) showed that lymphocytes progressed through the astrocytic glia limitans perivascularis to 319 
invade the surrounding neuropil (figure 4D; see arrowhead). Although anti-GFAP immunoreactivity 320 




perivascular regions with high immune cell density (figure 4F). Similar observations were made, if 322 
astrocytes were visualized with anti-ALDH1L1 antibodies (data not shown). To examine the presence 323 
of acute axonal injury around inflammatory infiltrates, we identified lesions in H&E-stained slides and 324 
stained adjacent sections with anti-APP antibodies, a marker for acute axonal injury (Hoflich, Beyer et 325 
al. 2016). The density of APP+ spheroids was assessed in concentric areas around the vessel centers. As 326 
shown in figures 4G/H, spheroid densities were highest in the immediate vicinity of the vessel and 327 
progressively declined with increasing distance. In summary, our results demonstrate that in the applied 328 
animal model oligodendrocyte apoptosis with concomitant microglia activation is sufficient to trigger 329 
peripheral immune cell recruitment into the forebrain after MOG35-55 immunization.  330 
 331 
We next aimed to identify the factors linked to peripheral immune cell recruitment in the cuprizone 332 
model. Total mRNA samples from the CC of control mice and mice intoxicated with cuprizone for 1 333 
week were analyzed using Affymetrix GeneChip® arrays. When a threshold of 1.5-fold regulation 334 
(control versus cuprizone) was applied, the expression of 344 probe sets was significantly up-regulated, 335 
whereas the expression of 227 probe sets genes was significantly reduced. As shown in figures 5A/B, 336 
2D principal components analysis (PCA) clearly revealed similarities between the individual samples 337 
(i.e., the formation of clusters), demonstrating the reliability of the experiment. For a better interpretation 338 
of our gene expression data, figure 5C shows a heatmap (each column: one individual animal), where 339 
red represents up-regulated genes and blue represents down-regulated genes in cuprizone-intoxicated 340 
versus control animals. Black represents unchanged gene expression levels. As demonstrated, the 341 
expression of well-known oligodendrocyte specific genes, such as Mag (myelin associated 342 
glycoprotein), Mal (myelin and lymphocyte protein), Aspa (aspartoacylase) or Mog (myelin 343 
oligodendrocyte glycoprotein) was significantly reduced after 1 week of cuprizone intoxication (lower-344 
right cluster in figure 5C). In contrast, the expression of chemokines which have been shown to be 345 
induced during the course of cuprizone-induced demyelination, such as Cxcl0 (Clarner, Janssen et al. 346 
2015) or Ccl3 (Janssen, Rickert et al. 2016) showed higher expression levels (upper-right cluster). For 347 
a complete list of up- and down-regulated genes see supplementary table 2. Next, we performed a gene 348 
ontology enrichment analysis with the detected down- and up-regulated genes, respectively. Computing 349 
genes for which expression was found to be down-regulated revealed greatest enrichments for the 350 
biological process terms ‘central nervous system myelination’ (28.5-fold enrichment), ‘cholesterol 351 
biosynthetic process’ (20.5-fold enrichment), ‘Schwann cell differentiation’ (16.2-fold enrichment), and 352 
‘regulation of gliogenesis’ (7.5-fold regulation). Computing genes for which expression was found to 353 
be up-regulated revealed greatest enrichments for the biological process terms ‘antigen processing and 354 
presentation of exogenous peptide antigen via MHC class I’ (51.9-fold enrichment), ‘positive regulation 355 
of tumor necrosis factor biosynthetic process’ (29.9-fold enrichment), ‘MyD88-dependent toll-like 356 
receptor signaling pathway’ (24.3-fold enrichment), and ‘response to interferon-alpha’ (22.7-fold 357 




activates pathways which are involved in the local (re-) activation of peripheral immune cells (see 359 
supplementary table 2 for a complete list of genes and expression values). 360 
One of the genes which displayed high expression induction was moesin (Msn). This protein belongs to 361 
the ezrin-radixin-moesin (ERM) family of proteins, which plays structural and regulatory roles in the 362 
rearrangement of plasma membrane flexibility and protrusions through interaction with cortical actin 363 
filaments and the plasma membrane (Pore and Gupta 2015). Since it has been reported that moesin is 364 
expressed in microglia/macrophages (Moon, Kim et al. 2011, Kashimoto, Yamanaka et al. 2013), and 365 
microglia activation is one characteristic feature of early cuprizone lesions, we focused on this particular 366 
ERM-protein.  367 
To verify our gene array data, and to visualize which cell type(s) express moesin, brain slides from 368 
control and 1 week cuprizone-intoxicated mice were processed for immunohistochemistry. As shown in 369 
figures 6A-C, low densities of moesin+ cells were found in the CC and cortex of control animals. 370 
Moesin+ cells showed morphological characteristics of either endothelial cells (Berryman, Franck et al. 371 
1993) (arrow in figure 6B’ and insert which shows a CD34/moesin double-stain) or microglia (arrow in 372 
figure 6C’). Densities of moesin+ cells were higher in both brain regions after 1 week cuprizone 373 
intoxication (figures 6D/E). To verify that the non-endothelial, moesin+ cell population belongs to the 374 
microglia cell lineage, adjacent sections were processed for IBA1/moesin immunofluorescence double 375 
staining experiments. As demonstrated in figures 6 F/G, there was a clear co-localization of the anti-376 
moesin and anti-IBA1 signal. Blinded evaluation revealed that virtually all moesin+ cells co-express 377 
IBA1 (data not shown). Furthermore, CD3/moesin immunofluorescence double staining experiments 378 
showed that lymphocytes expressed moesin as well (figure 6H). 379 
Finally, we analyzed moesin expression in the brains of MS patients. In normal appearing grey matter 380 
tissues (i.e., no evidence of demyelination), moesin was prominently localized to structures what 381 
appeared to be endothelial cells (arrowhead in figures 7A/B). Occasionally glial cells, possibly 382 
microglia, were moesin immunoreactive (see arrow in figure 7B). No apparent immunoreactivity was 383 
detected in what appeared to be neurons. Comparable to what we found in the cortex, structures what 384 
appeared to be endothelial cells and microglia cells were moesin+ in the normal appearing white matter 385 
(NAWM). Of note, the used antibody recognized the fine processes of scattered microglia (see arrow in 386 
figure 7C). Next, we analyzed moesin expression in six different MS lesions (i.e., three chronic active 387 
and three chronic inactive lesions). A representative chronic active lesion is shown in figures 7D-F and 388 
H. On the histopathological level, this lesion is characterized by focal demyelination (figures 7D/E), 389 
and accumulation of MHC-II+ microglia/monocytes particularly at the rim of the lesion (figure 7F/G). 390 
A high density of moesin+ cells was observed at the rim of chronic active MS lesions (figure 7I). 391 
Furthermore, as shown in figure 7J, moesin+ cells were observed in enlarged perivascular spaces, 392 
indicating that peripheral immune cells express moesin in MS as well. Slightly reduced densities of 393 




chronic inactive lesions (figure 7L). Blinded quantification of moesin+ cells in three chronic active 395 
lesions revealed lowest densities in the NAWM, and highest densities within the active lesion areas 396 
(figure 7N; p=0.1042). MHC-II/moesin immunofluorescence double staining experiments (figure 7M) 397 
verified that virtually all MHC-II+ cells express moesin. However, not all moesin+ cells were MHC-II+ 398 
(~88%), suggesting that moesin stains both activated and non-activated microglia/macrophages and 399 
endothelial cells.  400 
 401 
Discussion 402 
Here, we describe that early cuprizone lesions, which are characterized by oligodendrocyte apoptosis 403 
and microglia activation, trigger peripheral immune cell recruitment into the forebrain after MOG35-55 404 
immunization. On the one hand, this study clearly illustrates the significance of brain-intrinsic 405 
degenerative cascades for immune cell recruitment and, possibly, MS lesion formation. On the other 406 
hand, our findings add to the understanding of the Cup/EAE model, a practical and effective tool for 407 
studying immune cell recruitment into the forebrain. Of note, the model has great translational potential, 408 
as most imaging and pathological MS studies are performed in the forebrain. By contrast, most EAE 409 
studies focus on spinal cord tissues. 410 
Pathological changes associated with the formation of new inflammatory MS lesions are difficult to 411 
study, because such lesions are rarely fatal. Two main strategies can be pursued to understand underlying 412 
mechanisms of MS lesion formation: (i) To describe pathological findings in patients who died relatively 413 
early after the onset of a new symptomatic lesion, or (ii) to investigate brain biopsies of patients 414 
diagnosed with tumefactive MS, also called “pseudotumoral MS”, a well-recognized variant of MS 415 
(Hardy, Tobin et al. 2016, Totaro, Di Carmine et al. 2016). Following the first approach, Barnett and 416 
Prineas reported that the earliest pathological changes, described as prephagocytic lesions, consist of 417 
oligodendrocyte apoptosis and microglial activation associated with few lymphocytes and phagocytes 418 
in regions of relative myelin preservation. This was reported to be followed by the disappearance of 419 
oligodendrocytes and the presence of intramyelinic edema with tissue vacuolization. Finally, the myelin 420 
sheaths were fragmented and phagocytosed by macrophages in the presence of infiltrating T cells 421 
(Barnett and Prineas 2004). The earliest steps during the evolution of new, inflammatory lesions was, 422 
therefore, oligodendrocyte stress, paralleled by microglia activation. Similar observations were reported 423 
by others. For example, De Groot and colleagues subjected unfixed post-mortem brain slices to T(1)- 424 
and T(2)-weighted magnetic resonance imaging, followed by macroscopic and microscopic examination 425 
of the tissues. The authors described so-called ‘preactive’ lesions and speculated that this lesion type 426 
might represent one of the earliest stages during MS lesion development (De Groot, Bergers et al. 2001). 427 
Preactive lesions were observed throughout the normal-appearing white matter and were characterized 428 




2000). The presence of stressed oligodendrocytes in these preactive lesions was reported later (van 430 
Noort, Bsibsi et al. 2010) while van Horssen et al (2012) showed that the pre-active lesions were not 431 
associated with blood-brain barrier disruption, suggesting that an intrinsic trigger of innate immune 432 
activation, rather than extrinsic factors crossing a damaged blood-brain barrier, induces the formation 433 
of clusters of activated microglia (van Horssen, Singh et al. 2012). In another study, Marik and 434 
colleagues found abundant areas of microglial activation in the absence of detectable demyelination in 435 
human MS autopsy tissues. Such areas of microglial activation were localized in a broad zone 436 
surrounding the border of actively demyelinating lesions, and less frequently also presented as separate 437 
lesions, which occurred independently from actively demyelinating plaques (Marik, Felts et al. 2007). 438 
Of note, such ‘pre-demyelinating’ lesions were specific for pattern III demyelination, in which 439 
oligodendrocyte apoptosis is a major characteristic (Lucchinetti, Bruck et al. 2000). The authors 440 
suggested that focal areas of microglial activation may precede the formation of demyelinating plaques 441 
in MS patients exhibiting hypoxia-like, pattern III demyelination. Comparably, Henderson and 442 
colleagues demonstrated that early loss of oligodendrocytes along with macrophage activation is a 443 
prominent feature in tissues bordering rapidly expanding MS lesions. Of note, parenchymal 444 
lymphocytes were largely absent in such areas (Henderson, Barnett et al. 2009). In another study using 445 
EAE in marmosets, Maggi and colleagues compared serial in vivo magnetic resonance imaging (MRI) 446 
to postmortem tissues. Here the authors show that early inflammatory lesions in EAE are characterized 447 
by focal microglia and astrocyte activation in the absence of demyelination and parenchymal 448 
lymphocytes (Maggi, Macri et al. 2014). Likewise, in MS, serial MRI studies have shown that focal 449 
changes in the normal appearing white matter are present at locations that later develop into focal T2 450 
lesions that enhance with gadolinium (Filippi, Rocca et al. 1998, Narayana, Doyle et al. 1998). Such 451 
MRI studies have revealed that MS lesions are initiated several days or weeks before the appearance of 452 
the classical inflammatory demyelinating plaque (Filippi, Rocca et al. 1998, Narayana, Doyle et al. 453 
1998) indicating that the blood-brain barrier appears to be intact at the earliest stages of lesion 454 
development.  455 
Taken together, all these findings suggest a key role for brain intrinsic pathological processes during the 456 
earliest stages of MS lesion formation, and that areas of microglia activation precede the full-fledged 457 
inflammatory demyelination. Here, we demonstrate that several histopathological characteristics of 458 
early MS lesions are reproduced by a short-term cuprizone intoxication protocol, id est oligodendrocyte 459 
stress, focal microglia activation, absence of lymphocytes and absence of overt demyelination (see 460 
figure 1). These findings are in line with previous reports (Buschmann, Berger et al. 2012, Hagemeier, 461 
Lurbke et al. 2013, Clarner, Janssen et al. 2015). In the present study, oligodendrocyte stress was 462 
detected by either the visualization of apoptotic bodies or the presence of ATF3+ cells. Also not formally 463 
proven in the current study, we previously reported that activated caspase 3-expressing cells are found 464 
in close vicinity to CNPase-reactive fibers after short-term cuprizone intoxication (Buschmann, Berger 465 




(Goldberg, Daniel et al. 2013). The presence of apoptotic cells in the CC of cuprizone-intoxicated mice 467 
has been well reported by other groups (Acs and Komoly 2012, Hagemeier, Lurbke et al. 2013). 468 
Comparably, early microglia activation after short-term cuprizone intoxication has also been reported 469 
by us and other groups (Hagemeier, Lurbke et al. 2013, Clarner, Janssen et al. 2015, Krauspe, Dreher et 470 
al. 2015). Our studies thus support the finding that early cuprizone lesions are characterized by 471 
oligodendrocyte stress which leads to oligodendrocyte degeneration and concomitant microglia 472 
activation. Of note, whether minor demyelination is present in such early lesions remains to be clarified 473 
in future studies.  474 
How this relatively mild pathological process triggers peripheral immune cell recruitment is currently 475 
unclear. Early studies in the sixties showed that many focal CNS injuries can principally trigger the 476 
formation of EAE lesions in these damaged areas. This has been shown for electrical or thermal burns 477 
(Clark and Bogdanove 1955, Bogdanove and Clark 1957, Levine and Hoenig 1968), implantation of 478 
chemicals (Levine, Zimmerman et al. 1963), or anoxic injuries (Levine and Wenk 1967). The gene array 479 
analyses conducted in this study revealed that cuprizone-induced oligodendrocyte apoptosis is paralleled 480 
by expression induction of genes known to regulate the cytoskeletal network. One of these induced 481 
proteins is moesin. Moesin, a membrane-organizing extension spike protein, belongs to the 482 
ezrin/radixin/moesin family of proteins distributed in the plasma membrane in the cellular cortex. 483 
Collectively, these three proteins are also known as the ERM protein family. Under physiological 484 
conditions, microglial cells exhibit a highly ramified morphology characterized by motile processes that 485 
constantly monitor their immediate surrounding by extending and retracting their processes 486 
(Nimmerjahn, Kirchhoff et al. 2005). In case of a harmful event, the generation of effective immune 487 
responses by microglia necessitates their morphological transformation (or “activation”). During 488 
activation microglia cells retract their processes, and their cell bodies become hypertrophic. The ERM 489 
family proteins are in this context of particular interest as they orchestrate the assembly and stabilization 490 
of plasma membrane interactions through their ability to interact with transmembrane proteins and the 491 
cytoskeleton (Fehon, McClatchey et al. 2010). In doing so, they provide structural links to strengthen 492 
the cell cortex and facilitate several key cellular process, including the membrane dynamics, substrate 493 
adhesion, cell survival, determination of cell shape, polarity, formation of membrane protrusions, cell 494 
adhesion and motility (Pore and Gupta 2015, Pines, Levi et al. 2017). In this study, we demonstrated 495 
that induction of moesin expression is a robust and early event in the cuprizone model. 496 
Immunofluorescence double labelling experiments showed that besides endothelial cells, moesin is 497 
expressed by IBA1+ microglia. Furthermore, activated, LN3+ microglia/monocytes express moesin in 498 
MS lesions. It has been shown that moesin is expressed by, and functionally active in endothelial cells 499 
(Berryman, Franck et al. 1993, Schwartz-Albiez, Merling et al. 1995, Vitorino, Yeung et al. 2015). 500 
Expression and/or activation of moesin in microglia is less well appreciated, but microglia in the spinal 501 
cord were found to express moesin in a model of peripheral nerve injury (Kashimoto, Yamanaka et al. 502 




of the mouse cortex (Moon, Kim et al. 2011). In the latter study, moesin expression was also observed 504 
in resting microglia (Moon, Kim et al. 2011). In MS lesions we frequently found round, small moesin-505 
expressing cells, reminiscent of lymphocytes and moesin+ cells within the enlarged perivascular spaces 506 
of MS lesions (see figures 7I). At least in mice we can show that moesin expression is not restricted to 507 
monocytes, but can also be expressed by T cells (Schwartz-Albiez, Merling et al. 1995, Ansa-Addo, 508 
Zhang et al. 2017). Of note, it has recently been shown that moesin controls differentiation of regulatory 509 
T cells (Ansa-Addo, Zhang et al. 2017) and regulates lymphocyte trafficking (Nomachi, Yoshinaga et 510 
al. 2013). To our knowledge, this is the first report, demonstrating expression of moesin in MS lesions, 511 
however the function of moesin during lesion formation and progression is currently not known. Moesin 512 
knock-down animals develop normally and are fertile, with no obvious histological abnormalities in any 513 
of the tissues examined. Whether moesin deficient mice develop less severe demyelination in the 514 
cuprizone model, and whether these mice are protected from active EAE are unknown and may provide 515 
important information for lesion formation in MS.  516 
As mentioned in the results section of this manuscript, the mRNA expression of well-known 517 
oligodendrocyte specific genes was significantly reduced after 1 week of cuprizone intoxication. 518 
However, we did not find any evidence of demyelination at week 1 on the histochemical and 519 
immunohistochemical level (see figure 1). In a recent paper we were able to demonstrate that cuprizone-520 
induced oligodendrocyte apoptosis is paralleled by the activation of the endoplasmic-reticulum stress 521 
response (Fischbach, Nedelcu et al. 2018). One component of the endoplasmic-reticulum stress response 522 
is the selective and regulated degradation of mRNA, termed regulated IRE1‐dependent decay (RIDD), 523 
which relieves endoplasmic-reticulum stress by reducing the amount of the endoplasmic-reticulum 524 
protein load. We speculate that although myelin protein synthesis is reduced in the stressed 525 
oligodendrocytes, the myelin sheaths remain stable for several days or even weeks before demyelination 526 
is visible on the histological level.  527 
In summary, this study indicates that oligodendrocyte degeneration and concomitant microglia 528 
activation might trigger peripheral immune cell recruitment in MS, and thus, the formation of focal 529 
inflammatory lesions. A better understanding of the underlying mechanisms would allow approaches to 530 
suppress the development of inflammatory MS lesions at their earliest stages.  531 
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Figure 1: Histopathological characteristics of the 1 week cuprizone lesion 540 
(A) Representative H&E-staining to visualize apoptotic cells (arrows). (B) Anti-activating transcription 541 




demonstrate stressed oligodendrocytes. (C) Luxol fast blue (LFB)/periodic acid-Schiff (PAS) stain, (D) 543 
anti-proteolipid protein (myelin) 1 (PLP), (E) anti-myelin-associated glycoprotein (MAG) and (F) anti-544 
2',3'-cyclic nucleotide 3' phosphodiesterase (CNPase) stain to demonstrate the myelination status of the 545 
corpus callosum. (G) Anti- ionized calcium-binding adapter molecule (IBA1) stain to demonstrate 546 
microglia activation. (H) Anti-CD3 and (I) anti-CD4 stain to demonstrate absence of T-lymphocytes in 547 
the CC. (J) Representative electron-microscopy images to demonstrate intact myelination on the 548 
ultrastructural level. Arrowheads indicate myelinated axons. (K) Quantification of anti-myelin proteins 549 
densities (i.e., anti-PLP, anti-MAG and anti-CNPase) of control, 1 week (wk), 3 wks, and 5 wks 550 
cuprizone (cup) animals (n=4-5 per group). Statistical comparison was done using a one-way ANOVA 551 
with the obtained p-values corrected for multiple testing using the Dunnett’s post hoc test. Significant 552 
differences with respect to the control animals are indicated by *** p<0.001. 553 





Figure 2: Clinical disease progression and forebrain inflammatory cell infiltration 556 
(A) Clinical scores of control, experimental autoimmune encephalomyelitis (EAE) and 1wk cuprizone/ 557 
EAE (1wk Cup/EAE) mice. Five animals per experimental group, one representative experiment. The 558 




image shows the mean day of disease onset of EAE and 1wk Cup/EAE mice. The right image shows the 560 
mean maximum disease score of EAE and 1wk Cup/EAE mice. Comparison of the mean day of disease 561 
onset and maximum disease score were done using unpaired t-test. (B) Distribution of perivascular cuffs 562 
(PVCs) in the different treatment groups (H&E staining; black dots from one independent observer) at 563 
three brain levels (regions according to Sidman et al.). (C) Quantification of the number of PVCs at 564 
three distinct brain levels. At R215-235, 33 slides were analyzed in control animals (n=4), 44 slides in 565 
EAE animals (n=5), and 40 slides in 1wk Cup/EAE animals (n=5). At R245-265, 7 slides were analyzed 566 
in control animals (n=4), 7 slides in EAE animals (n=5), and 8 slides in 1wk Cup/EAE animals (n=5). 567 
At R275-295, 8 slides were analyzed in control animals (n=4), 10 slides in EAE animals (n=5), and 8 568 
slides in 1wk Cup/EAE animals (n=5). Comparison of the numbers of PVCs was done using one-way 569 
ANOVA with the obtained p-values corrected for multiple testing using the Tukey's post hoc test. 570 
Significant differences in between the three experimental groups are indicated by *p < 0.05, **p < 0.01, 571 





Figure 3: Correlation between severity of demyelination and forebrain inflammatory cell infiltration 574 
(A) Schematic depicting the experimental setup. (B) Anti-proteolipid protein (myelin) 1 (PLP)-stain 575 
(upper-row), Luxol fast blue (LFB)/periodic acid-Schiff (PAS) stain (middle-row) and anti-ionized 576 
calcium-binding adapter molecule-stain (lower-row, IBA1) to demonstrate demyelination and 577 
concomitant microgliosis of the corpus callosum. Animals were subjected to a 1 week or 3 weeks 578 
continuous cuprizone intoxication protocol. One additional group was intoxicated with cuprizone for 3 579 
weeks, followed by 2 weeks on normal chow before scarification. (C) Quantification of the number of 580 
perivascular cuffs (PVCs) per section at the level R215 in 1wk Cup/EAE (n=9), 3wks Cup/EAE (n=8) 581 




section was done using one-way ANOVA with the obtained p-values corrected for multiple testing using 583 
the Tukey's post hoc test. Significant differences in between the three experimental groups are indicated 584 
by *p < 0.05.  585 





Figure 4: Forebrain inflammatory cell infiltration and acute axonal injury. 588 
Representative perivascular cuffs (PVCs) of a 1wk Cup/EAE mouse at R225 (see figure 3 for grouping). 589 
(A/A’) H&E staining to demonstrate a perivascular lesions in which most immune cells are trapped in 590 
the enlarged perivascular space. (B/B’) Anti- ionized calcium-binding adapter molecule (IBA1) stain to 591 
demonstrate perivascular microglia and monocyte accumulation. (C/C’) Luxol fast blue (LFB)/periodic 592 




immune cells invaded the neuropil. (D) Anti- CD3 and anti-glial fibrillary acidic protein (GFAP) double 594 
stain to demonstrate migration of lymphocytes over the glia limitans perivascularis into the surrounding 595 
neuropil. Arrows indicate the glia limitans perivascularis whereas the arrowhead indicates a CD3+ 596 
lymphocyte in the perivascular neuropil. (E/F) Anti-GFAP stain to demonstrate astrocyte pathology 597 
around PVCs. (G) Anti-amyloid beta (A4) precursor protein (APP) stain to demonstrate acute axonal 598 
injury in perivascular areas as spheroids. Counterstaining with Hoechst 33258 (blue) to show the cell 599 
nuclei. (H) APP+ spheroid densities were quantified in concentric areas (up to 100 μm) from the vessel 600 
center. Inflamed (white columns) and normal vessels (black columns) were included. For each sector, 601 
25 perivascular regions with and without lesions (5-6 animals) were analyzed.  602 





Figure 5 605 
(A) Principal component 2D-analysis (PCA) of the gene expression data set. Each dot represents a 606 
corpus callosum sample. (B) Volcano plot of differentially abundant transcripts. (C) Heatmap in which 607 
genes have been grouped based on their pattern of gene expression. Each column represent one 608 
individual animal (control: 4 animals; 1 week cuprizone: 4 animals). The color and intensity of the boxes 609 
is used to represent changes (not absolute values) of gene expression. Red represents up-regulated genes 610 
and blue represents down-regulated genes. Black represents unchanged expression. Only genes 611 
significantly (FDR p-value < 0.05) differentially expressed with a minimal change in expression by 3-612 





Figure 6: Moesin expression in the cuprizone model 615 
(A) Schematic depicting the two principal regions (according to Sidman et al.) included in this part of 616 
the study, namely the midline of the corpus callosum (CC) (big box) and the primary somatosensory 617 
cortex area (small box). (B/B’) Representative anti-moesin stain of the CC in control animals. Insert in 618 
(B) shows a representative immunofluorescence double staining against CD34 (endothelial marker; 619 




magnification. (C/C’) Representative anti-moesin stain of the somatosensory cortex area in control 621 
animals. The vessel shown in (C) by the arrowhead is shown in C’ in higher magnification. The arrow 622 
in C’ highlights a moesin+ microglia cell. Anti-moesin stain of the corpus callosum (D) and 623 
somatosensory cortex area (E) after 1 week cuprizone-intoxication. (F/G) Anti-ionized calcium-binding 624 
adapter molecule (IBA1) / anti-moesin immunofluorescence double stain in control (F) and 1 week 625 
cuprizone-intoxicated mice (G). Note that moesin is expressed by IBA1+ microglia. (H) Anti-626 
moesin/anti-CD3 immunofluorescence double stain in 1wk Cup/EAE mice. Note that moesin is 627 
expressed by CD3+ lymphocytes (arrows).  628 





Figure 7: Moesin expression in multiple sclerosis lesions 631 
(A/B) Representative anti-moesin stains of the normal appearing grey matter (NAGM). Arrowheads 632 




moesin stain of the normal appearing white matter (NAWM). Arrowheads highlight a moesin+ blood 634 
vessel, the arrow highlights a moesin+ microglia. (D) Representative anti-proteolipid protein (myelin) 1 635 
(PLP)-stain of a chronic active lesion. Area highlighted by the box is shown in (E) in higher 636 
magnification. The star in (D) indicates NAWM. (E) The arrow highlights the center of the lesion with 637 
an inflamed vessel, the arrowhead highlights the border of the lesion. (F) Representative anti-MHC class 638 
II stain of the same section as shown in (D). The arrow highlights an inactive lesion center, the 639 
arrowhead highlights an active lesion border, which is shown in (G) in higher magnification. (H) 640 
Representative anti-moesin stain of the same section as shown in (D). The arrow highlights an inactive 641 
lesion center, the arrowhead highlights an active lesion border, the star highlights the NAWM. Moesin+ 642 
cells are found at high densities at the rim of the chronic-active lesion (I) and within enlarged 643 
perivascular spaces (J). Lower densities of moesin+ cells can be seen in the NAWM (K) and the inactive 644 
lesion center (L). (M) MHC-II/moesin immunofluorescence double staining of a chronic active lesion. 645 
(N) Quantification of moesin+ cell densities in the normal appearing white matter (NAWM), center and 646 
border of chronic active MS lesions. Mann-Withney test was performed to compare differences between 647 
the groups.  648 
(A-C) Scale bar: 40 µm. (D/F) Scale bar: 2 mm. (E) Scale bar: 150 µm. (G, I, J, K, L) Scale bar: 50 µm. 649 




Supplementary Tables 651 
Supplementary Table 1: Antibodies used for immunohistochemistry and immunofluorescence   652 
Primary antibodies
Antigen Manufacturer Order number Host Tissue Dilution Application AGR*
ALDH1L1 Abcam ab87117 rabbit murine 1:2 000 Immunohistochemistry none
1:5 000 Immunohistochemistry
1:2 500 Immunofluorescence
ATF3 Santa Cruz sc-188 rabbit murine 1:200 Immunohistochemistry Citrat  
CD3 Abcam ab-16669 rabbit murine 1:1 000 Immunohistochemistry Tris/EDTA
CD3 Abcam ab 11089 rat murine 1:100 Immunofluorescence Tris/EDTA
CD4 Abcam ab-183685 rabbit murine 1:1 000 Immunohistochemistry Tris/EDTA
CD34 Abcam ab8158 rat murine 1:50 Immunofluorescence Tris/EDTA
CNPase Abcam ab6313 mouse murine 1:2 000 Immunohistochemistry Tris/EDTA
GFAP Abcam ab4674 chicken murine 1:8 000 Immunohistochemistry Tris/EDTA
IBA1 Abcam Ab107159 goat murine 1:1 000 Immunofluorescence Tris/EDTA
IBA1 Wako 019-19 741 rabbit murine 1:5 000 Immunohistochemistry Tris/EDTA




1:100 Immunofluorescence Citrat  
1:250 Immunohistochemistry Tris/EDTA
1:100 Immunofluorescence Citrat  
murine
human
Biotinylated secondary antibodies 
goat anti-mouse IgG Vector BA-9200 goat 1:200 not applicable
goat anti-rabbit IgG Vector BA-1000 goat 1:200 not applicable
goat anti-chicken IgG Vector BA-9010 goat 1:200 not applicable
Flourescent secondary antibodies
Alexa 488 Invitrogen/Life Technologie A21202 donkey anti-mouse 1:1 000 not applicable
Alexa 488 Invitrogen/Life Technologie A11055 donkey anti-goat 1:200 not applicable
Alexa 594 Invitrogen/Life Technologie A21207 donkey anti-rabbit 1:200 not applicable
Alexa 594 Invitrogen/Life Technologie A21203 donkey anti-mouse 1:200 not applicable
Alexa 488 Invitrogen/Life Technologie A21206 donkey anti-rabbit 1:200 not applicable
Alexa 488 Invitrogen/Life Technologie A21208 donkey anti-rat 1:200 not applicable
Isotype Conentration Isotype Primary antibody Dilution
IgG2a Abcam ab18415 0.5mg/ml PLP 1:2 500 Immunohistochemistry
IgG1 Abcam ab18443 0.5mg/ml APPA4 1:2 500 Immunohistochemistry  
*antigen retrieval
Abcam ab151542






MHC-II Thermo-Fisher Scientific MA5-11966 mouse






Supplementary Table 2: List of genes with induced und reduced expression in the corpus callosum of 653 
cuprizone-intoxicated mice 654 
Gene Symbol Affy ProbeSet ID con Avg (log2) con S.D. cuprizone Avg (log2) cuprizone S.D. Fold Change cuprizone vs control (log2) FDR P-val con vs cuprizone
Mog 10450845 11,12 0,12 7,34 0,45 3,78136 2,05E-06
Mag 10562152 11,52 0,12 8,33 0,49 3,19061 6,47E-06
Mal 10487441 11,48 0,17 8,35 0,4 3,13586 3,77E-06
Aspa 10388254 9,18 0,25 6,37 0,48 2,81352 2,55E-05
Fa2h 10581824 10,39 0,09 7,81 0,29 2,57773 2,05E-06
Tmem88b 10519203 9,95 0,19 7,55 0,29 2,40599 3,77E-06
Ugt8a 10501963 11,16 0,13 8,91 0,28 2,24793 3,89E-06
Ppp1r14a 10551736 9,36 0,22 7,18 0,18 2,17632 2,83E-06
Tspan2 10494821 11,25 0,19 9,11 0,48 2,14405 9,65E-05
Cldn11 10491313 11,67 0,11 9,63 0,29 2,03914 4,72E-06
Opalin 10467529 9,39 0,15 7,43 0,58 1,95606 0,0004
Klk6 10552516 8,78 0,06 6,91 0,07 1,87184 1,95E-07
Gamt 10370766 9,56 0,15 7,73 0,07 1,82375 1,71E-06
S1pr5 10591494 9,02 0,32 7,23 0,17 1,79077 2,91E-05
Efhd1 10348194 9,92 0,16 8,14 0,16 1,77821 2,27E-06
Anln 10591781 9,07 0,07 7,3 0,37 1,76977 4,40E-05
Trf 10596148 11,53 0,22 9,79 0,48 1,73985 0,0003
Ermn 10482795 10,59 0,14 8,88 0,49 1,70929 0,0001
Cyp2j12 10514491 8,16 0,19 6,5 0,26 1,65992 3,09E-05
Plekhh1 10396800 8,78 0,12 7,13 0,41 1,65076 0,0002
Padi2 10509838 8,91 0,09 7,26 0,18 1,64616 3,19E-06
Adamts4 10351551 8,97 0,16 7,35 0,17 1,61353 8,22E-06
Hapln2 10499299 8,58 0,05 6,98 0,21 1,60407 5,64E-06
Cnp 10381154 11,85 0,14 10,26 0,28 1,58976 3,49E-05
Cmtm5 10415132 11,33 0,15 9,75 0,38 1,57531 0,0002
Ninj2 10541206 8,13 0,16 6,56 0,26 1,57046 4,63E-05
Galnt6 10432661 7,34 0,18 5,78 0,21 1,56071 3,16E-05
Plp1 10601888 13,41 0,11 11,86 0,3 1,54597 4,45E-05
Pllp 10580765 9,53 0,16 8,02 0,22 1,50080 2,45E-05
Car14 10500283 8,28 0,06 6,79 0,15 1,49057 2,10E-06
Erbb3 10373467 8,51 0,14 7,03 0,15 1,48027 8,22E-06
Sept4 10380067 10,42 0,15 8,95 0,17 1,46989 1,50E-05
Ttyh2 10382376 10,46 0,07 9,01 0,21 1,44890 9,76E-06
Mobp 10590269 11,65 0,12 10,22 0,47 1,43296 0,0005
Qdpr 10529895 11,25 0,13 9,81 0,27 1,43296 7,32E-05
Prr5l 10485378 7,55 0,09 6,12 0,32 1,42761 0,0001
Tmem63a 10352320 9,55 0,15 8,15 0,25 1,40054 4,21E-05
Nipal4 10385384 8,1 0,1 6,71 0,12 1,39506 2,27E-06
Plekhb1 10565910 11,95 0,05 10,58 0,25 1,37295 4,40E-05
Lpar1 10513256 9,66 0,12 8,29 0,12 1,36737 4,43E-06
Unc5b 10369388 8,7 0,1 7,36 0,19 1,34483 1,53E-05
Carns1 10464642 8,5 0,08 7,16 0,14 1,33914 6,89E-06
Plxnb3 10600249 9,02 0,1 7,69 0,05 1,32769 2,05E-06
Il33 10462442 9,41 0,21 8,09 0,34 1,31615 0,0005
Gjb1 10601161 7,61 0,24 6,35 0,32 1,26903 0,0004
Cntn2 10357705 9,96 0,07 8,7 0,1 1,26303 2,10E-06
Phldb1 10592891 9,6 0,17 8,35 0,1 1,24489 1,50E-05
Mbp 10457022 12,22 0,08 10,99 0,22 1,23266 3,56E-05
Cpm 10366546 8,32 0,13 7,11 0,25 1,20789 0,0001
Prr18 10441657 8,52 0,15 7,31 0,07 1,20789 8,22E-06
Efnb3 10387483 9,59 0,17 8,41 0,13 1,17632 2,99E-05
Smco3 10548871 8,3 0,07 7,12 0,32 1,17632 0,0001
Gsn 10471655 8,91 0,19 7,75 0,1 1,15704 4,07E-05
Mob3b 10512022 8,58 0,1 7,43 0,21 1,15056 5,80E-05
Pigz 10434993 9,21 0,12 8,06 0,18 1,14405 4,25E-05
Ccp110 10556640 9,58 0,06 8,44 0,04 1,13750 2,05E-06
Pde8a 10554521 8,94 0,18 7,8 0,1 1,13750 2,99E-05
Gm22290 10416897 4,27 0,54 3,15 0,37 1,11770 0,0302
Lrrn1 10540401 10,68 0,08 9,59 0,07 1,09761 3,77E-06
Apln 10604375 9,08 0,05 8 0,28 1,08406 0,0005
Myrf 10465916 9,6 0,1 8,52 0,28 1,07724 0,0004
D7Ertd443e 10568696 7,8 0,11 6,74 0,21 1,05658 0,0001
Fam57a 10378754 9,78 0,08 8,72 0,1 1,05658 1,26E-05
Ptgds 10480734 11,25 0,12 10,19 0,46 1,05658 0,0062
Cers2 10494227 10,22 0,15 9,17 0,2 1,04963 0,0002
Cd82 10485213 9,65 0,24 8,62 0,26 1,03562 0,0009
Cryab 10585214 11,59 0,09 10,56 0,16 1,03562 4,40E-05
Elovl7 10407072 9,14 0,18 8,11 0,19 1,03562 0,0002
Prrg1 10605493 7,53 0,1 6,5 0,08 1,02857 8,22E-06
Enpp2 10428619 11,75 0,28 10,74 0,57 1,00000 0,0252
Rhog 10566132 9,61 0,1 8,61 0,16 1,00000 9,84E-05
Gjc3 10534960 11,15 0,07 10,16 0,3 0,99277 0,0007
Sgk2 10478326 7,22 0,13 6,23 0,29 0,99277 0,0005
Gstm7 10501199 9,23 0,16 8,24 0,19 0,98550 0,0002
Mboat1 10404359 7,42 0,18 6,43 0,11 0,98550 6,44E-05
Mcam 10584674 9,25 0,07 8,27 0,13 0,97820 2,62E-05
Evi2a; Evi2b; Gm21975 10388958 8,41 0,14 7,43 0,21 0,97085 0,0004
Map6d1 10438456 10,26 0,06 9,3 0,03 0,97085 4,00E-06
Slc12a2 10455873 10,15 0,17 9,18 0,23 0,97085 0,0006
Plekhg3 10396671 8,1 0,19 7,13 0,18 0,96347 0,0006
Scd1 10467979 11,33 0,07 10,37 0,19 0,96347 9,84E-05
Tprn 10469957 7,82 0,06 6,85 0,12 0,96347 2,03E-05
Dock5 10421046 8,49 0,14 7,53 0,16 0,95606 0,0001
Trim59 10498620 7,88 0,25 6,92 0,33 0,95606 0,0043
Lgi3 10416279 10,97 0,12 10,02 0,23 0,94111 0,0002
Sh3gl3 10554588 9,3 0,15 8,37 0,13 0,93357 0,0002
Tppp3 10581266 9,87 0,15 8,93 0,18 0,93357 0,0003
Josd2 10552681 9,62 0,11 8,7 0,11 0,91839 6,40E-05
Tmem98 10379489 7,93 0,16 7,02 0,18 0,91839 0,0001
Hhip 10579894 8,33 0,18 7,42 0,16 0,91073 0,0003
Desi1 10430804 11,28 0,08 10,37 0,1 0,90304 2,81E-05
Trim13 10415784 9,32 0,1 8,42 0,08 0,90304 3,53E-05
Gjc2 10386352 7,93 0,09 7,04 0,09 0,89530 2,45E-05
Gm10863 10425265 7,84 0,18 6,95 0,04 0,89530 0,0001
Gm38481; Idi1 10482762 9,79 0,12 8,9 0,11 0,89530 6,42E-05
Idi1 10403413 10,02 0,15 9,13 0,11 0,88753 0,0001
Pacs2 10398936 10,29 0,08 9,4 0,17 0,88753 0,0002
Prkcq 10469255 8,68 0,14 7,79 0,12 0,88753 6,42E-05
Elovl1 10507539 9,67 0,15 8,8 0,18 0,87184 0,0011
Olfml1 10556076 7,91 0,15 7,05 0,23 0,86394 0,0004
Slc7a10 10552143 9,46 0,07 8,59 0,28 0,86394 0,0019
St18 10344679 8,06 0,23 7,19 0,32 0,86394 0,0022
Abca2 10470050 10,63 0,06 9,79 0,12 0,84800 4,08E-05
Ebp 10603485 8,73 0,06 7,88 0,13 0,84800 4,45E-05
Gatm 10487011 11,89 0,13 11,04 0,25 0,84800 0,0009
Bche 10498710 6,83 0,07 5,99 0,19 0,83996 0,0002
Cdc42ep2 10465278 8,85 0,11 8 0,09 0,83996 5,55E-05
Sytl2 10554863 9,51 0,08 8,67 0,04 0,83996 1,50E-05
Abca8a 10392522 5,94 0,11 5,11 0,18 0,83188 0,0003
Pla2g16 10461093 8,24 0,17 7,42 0,24 0,83188 0,0021
Sec14l5 10433373 7,61 0,13 6,78 0,24 0,83188 0,0009
Srd5a1 10410452 8,3 0,09 7,48 0,06 0,82375 2,99E-05
Dbndd2 10478495 8,73 0,08 7,92 0,13 0,81558 8,91E-05
Gm9791 10497752 9,38 0,14 8,57 0,1 0,81558 0,0003
Ctnna3 10363676 6,81 0,09 6 0,2 0,80735 0,0005
Mfge8 10564713 9,61 0,07 8,8 0,13 0,80735 6,44E-05
Mir219a-2; Gm3088 10481378 7,38 0,14 6,57 0,13 0,80735 0,0007
Rtkn2 10363743 6,65 0,1 5,85 0,09 0,80735 6,42E-05
Shtn1 10468762 9,23 0,09 8,42 0,15 0,80735 0,0001
Nmral1 10437432 7,71 0,18 6,91 0,06 0,79909 0,0003
Ano4 10371740 8,79 0,09 7,99 0,1 0,79077 6,42E-05
Rffl 10389087 8,42 0,02 7,63 0,12 0,79077 4,40E-05
Ldlr 10583732 8,76 0,13 7,98 0,08 0,78241 0,0002
Pls1 10595768 8,24 0,07 7,46 0,22 0,78241 0,0007
Arhgap23 10380773 9,37 0,11 8,59 0,03 0,77400 5,15E-05
Car2 10490923 11,35 0,14 10,58 0,28 0,77400 0,0074
Gng8 10550388 6,81 0,11 6,03 0,1 0,77400 0,0002
Mir100 10584589 6,24 0,19 5,47 0,3 0,77400 0,0077
Ankub1 10498302 7,44 0,13 6,67 0,36 0,76553 0,0041
Apod 10439009 12,02 0,07 11,26 0,16 0,76553 0,0004
Clmn 10402473 9,33 0,13 8,57 0,37 0,76553 0,0383
Insig1 10520362 9,88 0,24 9,12 0,18 0,76553 0,0017
Map7 10361956 9,63 0,07 8,87 0,08 0,76553 4,21E-05
Gstm5 10495243 10,05 0,19 9,3 0,1 0,75702 0,0009
Adssl1 10398859 8,54 0,21 7,79 0,2 0,74846 0,0014
Bcas1 10490061 10,21 0,15 9,46 0,21 0,74846 0,0016
Gm9895 10462343 6,94 0,22 6,19 0,16 0,74846 0,0019
Hmgcs1 10412466 10,5 0,11 9,75 0,06 0,74846 8,44E-05
Kctd4 10416505 7,52 0,17 6,77 0,18 0,74846 0,0007
Lrp4 10473880 8,81 0,13 8,07 0,05 0,74846 0,0001
Myo1d 10389022 8,87 0,15 8,12 0,2 0,74846 0,0013
Slc44a1 10505008 10,67 0,11 9,92 0,04 0,74846 9,84E-05
Enpp6 10571715 8,46 0,08 7,72 0,1 0,73985 9,84E-05
Sp7 10433003 6,55 0,24 5,81 0,2 0,73985 0,0025
Usp54 10417920 9,37 0,11 8,63 0,16 0,73985 0,0006
Chil1 10349968 7,81 0,15 7,07 0,37 0,73118 0,0147
Gpr37 10543466 9,87 0,18 9,15 0,38 0,73118 0,0066
Nkain2 10368585 10,98 0,04 10,26 0,14 0,72247 0,0003
Pmp22 10376950 10,43 0,02 9,71 0,23 0,72247 0,0018
St6galnac3 10502890 8,25 0,1 7,52 0,03 0,72247 6,40E-05
Tnni1 10350149 7,65 0,14 6,93 0,19 0,72247 0,0007
Fah 10565315 8,82 0,12 8,11 0,19 0,71370 0,0011
Ndrg1 10429140 10,89 0,04 10,18 0,25 0,71370 0,0041
Rnf122 10571214 8,92 0,08 8,21 0,1 0,71370 0,0001
Sccpdh 10352178 9,5 0,2 8,78 0,23 0,71370 0,0088
Enpp1 10368289 7,76 0,07 7,06 0,11 0,70487 0,0002
Itgb4 10382713 7,82 0,12 7,12 0,19 0,70487 0,0010
Tppp 10406171 10,83 0,05 10,13 0,05 0,70487 3,16E-05
Adamtsl4 10500183 8,08 0,1 7,38 0,1 0,69599 0,0001
Pik3c2b 10349834 9,56 0,01 8,87 0,1 0,69599 6,63E-05
Tmeff1 10504891 10,5 0,08 9,81 0,12 0,69599 0,0004
Carhsp1 10437590 8,68 0,15 7,99 0,14 0,68706 0,0006
Dhcr7 10559312 9,02 0,1 8,34 0,14 0,68706 0,0005
Myo1d 10389025 9,2 0,21 8,51 0,15 0,68706 0,0008
Pip4k2a 10480347 10,85 0,12 10,16 0,12 0,68706 0,0007
Dhcr24 10506571 9,92 0,12 9,24 0,17 0,67807 0,0015
Hopx 10530819 8,47 0,22 7,79 0,03 0,67807 0,0013
Sema4d 10409236 9,67 0,06 9 0,11 0,67807 0,0002
Usp54 10417912 10,23 0,08 9,55 0,18 0,67807 0,0010
Foxn3 10402063 9,69 0,14 9,02 0,13 0,66903 0,0017
Gal3st1 10373826 7,4 0,07 6,73 0,13 0,66903 0,0005
Kndc1 10558548 9,97 0,12 9,3 0,24 0,66903 0,0047
Rasgrp3 10446965 8,74 0,09 8,07 0,11 0,66903 0,0002
Myoc 10351131 6,37 0,18 5,72 0,33 0,65992 0,0209
Nrbp2 10429754 10,92 0,08 10,26 0,18 0,65992 0,0018
Rcbtb1 10415662 9,59 0,08 8,93 0,04 0,65992 7,32E-05
Smad7 10456745 8,69 0,16 8,04 0,11 0,65992 0,0031
Thbs4 10411082 8,79 0,21 8,13 0,33 0,65992 0,0267
Tubb4a 10452295 12,25 0,01 11,59 0,09 0,65992 6,43E-05
B3galt5 10437191 8,7 0,13 8,04 0,12 0,65076 0,0006
Daam2 10451679 8,93 0,19 8,28 0,23 0,65076 0,0056
Polr3e 10557058 8,54 0,13 7,89 0,22 0,65076 0,0033
Cacna2d4 10541144 7,22 0,2 6,58 0,23 0,64155 0,0162
Cdk18 10357676 9,25 0,13 8,61 0,18 0,64155 0,0017
Cyp27a1 10347481 8,17 0,09 7,52 0,13 0,64155 0,0004
Cyp51 10527920 9,1 0,1 8,46 0,07 0,64155 0,0002
Klhl4 10601519 8,72 0,16 8,08 0,4 0,64155 0,0188
Plpp2 10370552 8,56 0,14 7,92 0,12 0,64155 0,0005
Slc4a2 10520187 8,64 0,15 8 0,04 0,64155 0,0010
Csrp1 10350136 11,96 0,07 11,33 0,14 0,63227 0,0005
Fam83d 10478160 6,74 0,18 6,1 0,04 0,63227 0,0011
Prima1 10402318 8,19 0,08 7,55 0,16 0,63227 0,0011
Ptprd 10513957 11,35 0,05 10,72 0,14 0,63227 0,0008
Sema4d 10409240 9,28 0,07 8,64 0,12 0,63227 0,0005
Sorbs3 10421269 8,52 0,08 7,89 0,09 0,63227 0,0003
Trp53inp2 10477644 11,08 0,05 10,44 0,11 0,63227 0,0002
Plekhf1 10562576 7,49 0,3 6,86 0,2 0,62293 0,0161
Tmem125 10515797 7,42 0,11 6,8 0,17 0,62293 0,0029
Gpr62 10596489 7,93 0,13 7,32 0,14 0,61353 0,0019
Il17rb 10418341 6,82 0,06 6,21 0,12 0,61353 0,0007
Nfe2l3 10538275 7,56 0,1 6,95 0,1 0,61353 0,0002
Ranbp3l 10422946 5,99 0,06 5,37 0,16 0,61353 0,0011
Rhou 10576386 9,71 0,14 9,09 0,14 0,61353 0,0041
Zdhhc9 10604380 10,23 0,07 9,62 0,12 0,61353 0,0004
March8 10541049 9,11 0,07 8,5 0,18 0,60407 0,0013
Sox8 10448967 9,9 0,04 9,3 0,06 0,60407 9,38E-05
Tmem229a 10543460 8,71 0,17 8,11 0,17 0,60407 0,0259
Trim13 10395198 7,32 0,09 6,71 0,08 0,60407 0,0003
Gpc5 10416960 8,15 0,1 7,55 0,15 0,59455 0,0014
Jam3 10591967 8,24 0,15 7,65 0,17 0,59455 0,0041
Marcksl1 10508465 8,14 0,15 7,55 0,15 0,59455 0,0012
Nkx2-9 10400479 7,21 0,06 6,61 0,2 0,59455 0,0027
Plxnb1 10589368 9,18 0,06 8,58 0,15 0,59455 0,0020
Rlbp1 10564726 7,51 0,09 6,92 0,05 0,59455 0,0002
Slc1a2 10474141 12,12 0,09 11,53 0,1 0,59455 0,0005
Tspan15 10369531 8,2 0,19 7,61 0,11 0,59455 0,0035
Atp8b1 10459421 7,44 0,09 6,85 0,14 0,58496 0,0012





Gene Symbol Affy ProbeSet ID con Avg (log2) con S.D. cuprizone Avg (log2) cuprizone S.D. Fold Change cuprizone vs control (log2) FDR P-val con vs cuprizone
Mog 10450845 11,12 0,12 7,34 0,45 3,78136 2,05E-06
Mag 10562152 11,52 0,12 8,33 0,49 3,19061 6,47E-06
Mal 10487441 11,48 0,17 8,35 0,4 3,13586 3,77E-06
Aspa 10388254 9,18 0,25 6,37 0,48 2,81352 2,55E-05
Fa2h 10581824 10,39 0,09 7,81 0,29 2,57773 2,05E-06
Tmem88b 10519203 9,95 0,19 7,55 0,29 2,40599 3,77E-06
Ugt8a 10501963 11,16 0,13 8,91 0,28 2,24793 3,89E-06
Ppp1r14a 10551736 9,36 0,22 7,18 0,18 2,17632 2,83E-06
Tspan2 10494821 11,25 0,19 9,11 0,48 2,14405 9,65E-05
Cldn11 10491313 11,67 0,11 9,63 0,29 2,03914 4,72E-06
Opalin 10467529 9,39 0,15 7,43 0,58 1,95606 0,0004
Klk6 10552516 8,78 0,06 6,91 0,07 1,87184 1,95E-07
Gamt 10370766 9,56 0,15 7,73 0,07 1,82375 1,71E-06
S1pr5 10591494 9,02 0,32 7,23 0,17 1,79077 2,91E-05
Efhd1 10348194 9,92 0,16 8,14 0,16 1,77821 2,27E-06
Anln 10591781 9,07 0,07 7,3 0,37 1,76977 4,40E-05
Trf 10596148 11,53 0,22 9,79 0,48 1,73985 0,0003
Ermn 10482795 10,59 0,14 8,88 0,49 1,70929 0,0001
Cyp2j12 10514491 8,16 0,19 6,5 0,26 1,65992 3,09E-05
Plekhh1 10396800 8,78 0,12 7,13 0,41 1,65076 0,0002
Padi2 10509838 8,91 0,09 7,26 0,18 1,64616 3,19E-06
Adamts4 10351551 8,97 0,16 7,35 0,17 1,61353 8,22E-06
Hapln2 10499299 8,58 0,05 6,98 0,21 1,60407 5,64E-06
Cnp 10381154 11,85 0,14 10,26 0,28 1,58976 3,49E-05
Cmtm5 10415132 11,33 0,15 9,75 0,38 1,57531 0,0002
Ninj2 10541206 8,13 0,16 6,56 0,26 1,57046 4,63E-05
Galnt6 10432661 7,34 0,18 5,78 0,21 1,56071 3,16E-05
Plp1 10601888 13,41 0,11 11,86 0,3 1,54597 4,45E-05
Pllp 10580765 9,53 0,16 8,02 0,22 1,50080 2,45E-05
Car14 10500283 8,28 0,06 6,79 0,15 1,49057 2,10E-06
Erbb3 10373467 8,51 0,14 7,03 0,15 1,48027 8,22E-06
Sept4 10380067 10,42 0,15 8,95 0,17 1,46989 1,50E-05
Ttyh2 10382376 10,46 0,07 9,01 0,21 1,44890 9,76E-06
Mobp 10590269 11,65 0,12 10,22 0,47 1,43296 0,0005
Qdpr 10529895 11,25 0,13 9,81 0,27 1,43296 7,32E-05
Prr5l 10485378 7,55 0,09 6,12 0,32 1,42761 0,0001
Tmem63a 10352320 9,55 0,15 8,15 0,25 1,40054 4,21E-05
Nipal4 10385384 8,1 0,1 6,71 0,12 1,39506 2,27E-06
Plekhb1 10565910 11,95 0,05 10,58 0,25 1,37295 4,40E-05
Lpar1 10513256 9,66 0,12 8,29 0,12 1,36737 4,43E-06
Unc5b 10369388 8,7 0,1 7,36 0,19 1,34483 1,53E-05
Carns1 10464642 8,5 0,08 7,16 0,14 1,33914 6,89E-06
Plxnb3 10600249 9,02 0,1 7,69 0,05 1,32769 2,05E-06
Il33 10462442 9,41 0,21 8,09 0,34 1,31615 0,0005
Gjb1 10601161 7,61 0,24 6,35 0,32 1,26903 0,0004
Cntn2 10357705 9,96 0,07 8,7 0,1 1,26303 2,10E-06
Phldb1 10592891 9,6 0,17 8,35 0,1 1,24489 1,50E-05
Mbp 10457022 12,22 0,08 10,99 0,22 1,23266 3,56E-05
Cpm 10366546 8,32 0,13 7,11 0,25 1,20789 0,0001
Prr18 10441657 8,52 0,15 7,31 0,07 1,20789 8,22E-06
Efnb3 10387483 9,59 0,17 8,41 0,13 1,17632 2,99E-05
Smco3 10548871 8,3 0,07 7,12 0,32 1,17632 0,0001
Gsn 10471655 8,91 0,19 7,75 0,1 1,15704 4,07E-05
Mob3b 10512022 8,58 0,1 7,43 0,21 1,15056 5,80E-05
Pigz 10434993 9,21 0,12 8,06 0,18 1,14405 4,25E-05
Ccp110 10556640 9,58 0,06 8,44 0,04 1,13750 2,05E-06
Pde8a 10554521 8,94 0,18 7,8 0,1 1,13750 2,99E-05
Gm22290 10416897 4,27 0,54 3,15 0,37 1,11770 0,0302
Lrrn1 10540401 10,68 0,08 9,59 0,07 1,09761 3,77E-06
Apln 10604375 9,08 0,05 8 0,28 1,08406 0,0005
Myrf 10465916 9,6 0,1 8,52 0,28 1,07724 0,0004
D7Ertd443e 10568696 7,8 0,11 6,74 0,21 1,05658 0,0001
Fam57a 10378754 9,78 0,08 8,72 0,1 1,05658 1,26E-05
Ptgds 10480734 11,25 0,12 10,19 0,46 1,05658 0,0062
Cers2 10494227 10,22 0,15 9,17 0,2 1,04963 0,0002
Cd82 10485213 9,65 0,24 8,62 0,26 1,03562 0,0009
Cryab 10585214 11,59 0,09 10,56 0,16 1,03562 4,40E-05
Elovl7 10407072 9,14 0,18 8,11 0,19 1,03562 0,0002
Prrg1 10605493 7,53 0,1 6,5 0,08 1,02857 8,22E-06
Enpp2 10428619 11,75 0,28 10,74 0,57 1,00000 0,0252
Rhog 10566132 9,61 0,1 8,61 0,16 1,00000 9,84E-05
Gjc3 10534960 11,15 0,07 10,16 0,3 0,99277 0,0007
Sgk2 10478326 7,22 0,13 6,23 0,29 0,99277 0,0005
Gstm7 10501199 9,23 0,16 8,24 0,19 0,98550 0,0002
Mboat1 10404359 7,42 0,18 6,43 0,11 0,98550 6,44E-05
Mcam 10584674 9,25 0,07 8,27 0,13 0,97820 2,62E-05
Evi2a; Evi2b; Gm21975 10388958 8,41 0,14 7,43 0,21 0,97085 0,0004
Map6d1 10438456 10,26 0,06 9,3 0,03 0,97085 4,00E-06
Slc12a2 10455873 10,15 0,17 9,18 0,23 0,97085 0,0006
Plekhg3 10396671 8,1 0,19 7,13 0,18 0,96347 0,0006
Scd1 10467979 11,33 0,07 10,37 0,19 0,96347 9,84E-05
Tprn 10469957 7,82 0,06 6,85 0,12 0,96347 2,03E-05
Dock5 10421046 8,49 0,14 7,53 0,16 0,95606 0,0001
Trim59 10498620 7,88 0,25 6,92 0,33 0,95606 0,0043
Lgi3 10416279 10,97 0,12 10,02 0,23 0,94111 0,0002
Sh3gl3 10554588 9,3 0,15 8,37 0,13 0,93357 0,0002
Tppp3 10581266 9,87 0,15 8,93 0,18 0,93357 0,0003
Josd2 10552681 9,62 0,11 8,7 0,11 0,91839 6,40E-05
Tmem98 10379489 7,93 0,16 7,02 0,18 0,91839 0,0001
Hhip 10579894 8,33 0,18 7,42 0,16 0,91073 0,0003
Desi1 10430804 11,28 0,08 10,37 0,1 0,90304 2,81E-05
Trim13 10415784 9,32 0,1 8,42 0,08 0,90304 3,53E-05
Gjc2 10386352 7,93 0,09 7,04 0,09 0,89530 2,45E-05
Gm10863 10425265 7,84 0,18 6,95 0,04 0,89530 0,0001
Gm38481; Idi1 10482762 9,79 0,12 8,9 0,11 0,89530 6,42E-05
Idi1 10403413 10,02 0,15 9,13 0,11 0,88753 0,0001
Pacs2 10398936 10,29 0,08 9,4 0,17 0,88753 0,0002
Prkcq 10469255 8,68 0,14 7,79 0,12 0,88753 6,42E-05
Elovl1 10507539 9,67 0,15 8,8 0,18 0,87184 0,0011
Olfml1 10556076 7,91 0,15 7,05 0,23 0,86394 0,0004
Slc7a10 10552143 9,46 0,07 8,59 0,28 0,86394 0,0019
St18 10344679 8,06 0,23 7,19 0,32 0,86394 0,0022
Abca2 10470050 10,63 0,06 9,79 0,12 0,84800 4,08E-05
Ebp 10603485 8,73 0,06 7,88 0,13 0,84800 4,45E-05
Gatm 10487011 11,89 0,13 11,04 0,25 0,84800 0,0009
Bche 10498710 6,83 0,07 5,99 0,19 0,83996 0,0002
Cdc42ep2 10465278 8,85 0,11 8 0,09 0,83996 5,55E-05
Sytl2 10554863 9,51 0,08 8,67 0,04 0,83996 1,50E-05
Abca8a 10392522 5,94 0,11 5,11 0,18 0,83188 0,0003
Pla2g16 10461093 8,24 0,17 7,42 0,24 0,83188 0,0021
Sec14l5 10433373 7,61 0,13 6,78 0,24 0,83188 0,0009
Srd5a1 10410452 8,3 0,09 7,48 0,06 0,82375 2,99E-05
Dbndd2 10478495 8,73 0,08 7,92 0,13 0,81558 8,91E-05
Gm9791 10497752 9,38 0,14 8,57 0,1 0,81558 0,0003
Ctnna3 10363676 6,81 0,09 6 0,2 0,80735 0,0005
Mfge8 10564713 9,61 0,07 8,8 0,13 0,80735 6,44E-05
Mir219a-2; Gm3088 10481378 7,38 0,14 6,57 0,13 0,80735 0,0007
Rtkn2 10363743 6,65 0,1 5,85 0,09 0,80735 6,42E-05
Shtn1 10468762 9,23 0,09 8,42 0,15 0,80735 0,0001
Nmral1 10437432 7,71 0,18 6,91 0,06 0,79909 0,0003
Ano4 10371740 8,79 0,09 7,99 0,1 0,79077 6,42E-05
Rffl 10389087 8,42 0,02 7,63 0,12 0,79077 4,40E-05
Ldlr 10583732 8,76 0,13 7,98 0,08 0,78241 0,0002
Pls1 10595768 8,24 0,07 7,46 0,22 0,78241 0,0007
Arhgap23 10380773 9,37 0,11 8,59 0,03 0,77400 5,15E-05
Car2 10490923 11,35 0,14 10,58 0,28 0,77400 0,0074
Gng8 10550388 6,81 0,11 6,03 0,1 0,77400 0,0002
Mir100 10584589 6,24 0,19 5,47 0,3 0,77400 0,0077
Ankub1 10498302 7,44 0,13 6,67 0,36 0,76553 0,0041
Apod 10439009 12,02 0,07 11,26 0,16 0,76553 0,0004
Clmn 10402473 9,33 0,13 8,57 0,37 0,76553 0,0383
Insig1 10520362 9,88 0,24 9,12 0,18 0,76553 0,0017
Map7 10361956 9,63 0,07 8,87 0,08 0,76553 4,21E-05
Gstm5 10495243 10,05 0,19 9,3 0,1 0,75702 0,0009
Adssl1 10398859 8,54 0,21 7,79 0,2 0,74846 0,0014
Bcas1 10490061 10,21 0,15 9,46 0,21 0,74846 0,0016
Gm9895 10462343 6,94 0,22 6,19 0,16 0,74846 0,0019
Hmgcs1 10412466 10,5 0,11 9,75 0,06 0,74846 8,44E-05
Kctd4 10416505 7,52 0,17 6,77 0,18 0,74846 0,0007
Lrp4 10473880 8,81 0,13 8,07 0,05 0,74846 0,0001
Myo1d 10389022 8,87 0,15 8,12 0,2 0,74846 0,0013
Slc44a1 10505008 10,67 0,11 9,92 0,04 0,74846 9,84E-05
Enpp6 10571715 8,46 0,08 7,72 0,1 0,73985 9,84E-05
Sp7 10433003 6,55 0,24 5,81 0,2 0,73985 0,0025
Usp54 10417920 9,37 0,11 8,63 0,16 0,73985 0,0006
Chil1 10349968 7,81 0,15 7,07 0,37 0,73118 0,0147
Gpr37 10543466 9,87 0,18 9,15 0,38 0,73118 0,0066
Nkain2 10368585 10,98 0,04 10,26 0,14 0,72247 0,0003
Pmp22 10376950 10,43 0,02 9,71 0,23 0,72247 0,0018
St6galnac3 10502890 8,25 0,1 7,52 0,03 0,72247 6,40E-05
Tnni1 10350149 7,65 0,14 6,93 0,19 0,72247 0,0007
Fah 10565315 8,82 0,12 8,11 0,19 0,71370 0,0011
Ndrg1 10429140 10,89 0,04 10,18 0,25 0,71370 0,0041
Rnf122 10571214 8,92 0,08 8,21 0,1 0,71370 0,0001
Sccpdh 10352178 9,5 0,2 8,78 0,23 0,71370 0,0088
Enpp1 10368289 7,76 0,07 7,06 0,11 0,70487 0,0002
Itgb4 10382713 7,82 0,12 7,12 0,19 0,70487 0,0010
Tppp 10406171 10,83 0,05 10,13 0,05 0,70487 3,16E-05
Adamtsl4 10500183 8,08 0,1 7,38 0,1 0,69599 0,0001
Pik3c2b 10349834 9,56 0,01 8,87 0,1 0,69599 6,63E-05
Tmeff1 10504891 10,5 0,08 9,81 0,12 0,69599 0,0004
Carhsp1 10437590 8,68 0,15 7,99 0,14 0,68706 0,0006
Dhcr7 10559312 9,02 0,1 8,34 0,14 0,68706 0,0005
Myo1d 10389025 9,2 0,21 8,51 0,15 0,68706 0,0008
Pip4k2a 10480347 10,85 0,12 10,16 0,12 0,68706 0,0007
Dhcr24 10506571 9,92 0,12 9,24 0,17 0,67807 0,0015
Hopx 10530819 8,47 0,22 7,79 0,03 0,67807 0,0013
Sema4d 10409236 9,67 0,06 9 0,11 0,67807 0,0002
Usp54 10417912 10,23 0,08 9,55 0,18 0,67807 0,0010
Foxn3 10402063 9,69 0,14 9,02 0,13 0,66903 0,0017
Gal3st1 10373826 7,4 0,07 6,73 0,13 0,66903 0,0005
Kndc1 10558548 9,97 0,12 9,3 0,24 0,66903 0,0047
Rasgrp3 10446965 8,74 0,09 8,07 0,11 0,66903 0,0002
Myoc 10351131 6,37 0,18 5,72 0,33 0,65992 0,0209
Nrbp2 10429754 10,92 0,08 10,26 0,18 0,65992 0,0018
Rcbtb1 10415662 9,59 0,08 8,93 0,04 0,65992 7,32E-05
Smad7 10456745 8,69 0,16 8,04 0,11 0,65992 0,0031
Thbs4 10411082 8,79 0,21 8,13 0,33 0,65992 0,0267
Tubb4a 10452295 12,25 0,01 11,59 0,09 0,65992 6,43E-05
B3galt5 10437191 8,7 0,13 8,04 0,12 0,65076 0,0006
Daam2 10451679 8,93 0,19 8,28 0,23 0,65076 0,0056
Polr3e 10557058 8,54 0,13 7,89 0,22 0,65076 0,0033
Cacna2d4 10541144 7,22 0,2 6,58 0,23 0,64155 0,0162
Cdk18 10357676 9,25 0,13 8,61 0,18 0,64155 0,0017
Cyp27a1 10347481 8,17 0,09 7,52 0,13 0,64155 0,0004
Cyp51 10527920 9,1 0,1 8,46 0,07 0,64155 0,0002
Klhl4 10601519 8,72 0,16 8,08 0,4 0,64155 0,0188
Plpp2 10370552 8,56 0,14 7,92 0,12 0,64155 0,0005
Slc4a2 10520187 8,64 0,15 8 0,04 0,64155 0,0010
Csrp1 10350136 11,96 0,07 11,33 0,14 0,63227 0,0005
Fam83d 10478160 6,74 0,18 6,1 0,04 0,63227 0,0011
Prima1 10402318 8,19 0,08 7,55 0,16 0,63227 0,0011
Ptprd 10513957 11,35 0,05 10,72 0,14 0,63227 0,0008
Sema4d 10409240 9,28 0,07 8,64 0,12 0,63227 0,0005
Sorbs3 10421269 8,52 0,08 7,89 0,09 0,63227 0,0003
Trp53inp2 10477644 11,08 0,05 10,44 0,11 0,63227 0,0002
Plekhf1 10562576 7,49 0,3 6,86 0,2 0,62293 0,0161
Tmem125 10515797 7,42 0,11 6,8 0,17 0,62293 0,0029
Gpr62 10596489 7,93 0,13 7,32 0,14 0,61353 0,0019
Il17rb 10418341 6,82 0,06 6,21 0,12 0,61353 0,0007
Nfe2l3 10538275 7,56 0,1 6,95 0,1 0,61353 0,0002
Ranbp3l 10422946 5,99 0,06 5,37 0,16 0,61353 0,0011
Rhou 10576386 9,71 0,14 9,09 0,14 0,61353 0,0041
Zdhhc9 10604380 10,23 0,07 9,62 0,12 0,61353 0,0004
March8 10541049 9,11 0,07 8,5 0,18 0,60407 0,0013
Sox8 10448967 9,9 0,04 9,3 0,06 0,60407 9,38E-05
Tmem229a 10543460 8,71 0,17 8,11 0,17 0,60407 0,0259
Trim13 10395198 7,32 0,09 6,71 0,08 0,60407 0,0003
Gpc5 10416960 8,15 0,1 7,55 0,15 0,59455 0,0014
Jam3 10591967 8,24 0,15 7,65 0,17 0,59455 0,0041
Marcksl1 10508465 8,14 0,15 7,55 0,15 0,59455 0,0012
Nkx2-9 10400479 7,21 0,06 6,61 0,2 0,59455 0,0027
Plxnb1 10589368 9,18 0,06 8,58 0,15 0,59455 0,0020
Rlbp1 10564726 7,51 0,09 6,92 0,05 0,59455 0,0002
Slc1a2 10474141 12,12 0,09 11,53 0,1 0,59455 0,0005
Tspan15 10369531 8,2 0,19 7,61 0,11 0,59455 0,0035
Atp8b1 10459421 7,44 0,09 6,85 0,14 0,58496 0,0012
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Mog 10450845 11,12 0,12 7,34 0,45 3,78136 2,05E-06
Mag 10562152 11,52 0,12 8,33 0,49 3,19061 6,47E-06
Mal 10487441 11,48 0,17 8,35 0,4 3,13586 3,77E-06
Aspa 10388254 9,18 0,25 6,37 0,48 2,81352 2,55E-05
Fa2h 10581824 10,39 0,09 7,81 0,29 2,57773 2,05E-06
Tmem88b 10519203 9,95 0,19 7,55 0,29 2,40599 3,77E-06
Ugt8a 10501963 11,16 0,13 8,91 0,28 2,24793 3,89E-06
Ppp1r14a 10551736 9,36 0,22 7,18 0,18 2,17632 2,83E-06
Tspan2 10494821 11,25 0,19 9,11 0,48 2,14405 9,65E-05
Cldn11 10491313 11,67 0,11 9,63 0,29 2,03914 4,72E-06
Opalin 10467529 9,39 0,15 7,43 0,58 1,95606 0,0004
Klk6 10552516 8,78 0,06 6,91 0,07 1,87184 1,95E-07
Gamt 10370766 9,56 0,15 7,73 0,07 1,82375 1,71E-06
S1pr5 10591494 9,02 0,32 7,23 0,17 1,79077 2,91E-05
Efhd1 10348194 9,92 0,16 8,14 0,16 1,77821 2,27E-06
Anln 10591781 9,07 0,07 7,3 0,37 1,76977 4,40E-05
Trf 10596148 11,53 0,22 9,79 0,48 1,73985 0,0003
Ermn 10482795 10,59 0,14 8,88 0,49 1,70929 0,0001
Cyp2j12 10514491 8,16 0,19 6,5 0,26 1,65992 3,09E-05
Plekhh1 10396800 8,78 0,12 7,13 0,41 1,65076 0,0002
Padi2 10509838 8,91 0,09 7,26 0,18 1,64616 3,19E-06
Adamts4 10351551 8,97 0,16 7,35 0,17 1,61353 8,22E-06
Hapln2 10499299 8,58 0,05 6,98 0,21 1,60407 5,64E-06
Cnp 10381154 11,85 0,14 10,26 0,28 1,58976 3,49E-05
Cmtm5 10415132 11,33 0,15 9,75 0,38 1,57531 0,0002
Ninj2 10541206 8,13 0,16 6,56 0,26 1,57046 4,63E-05
Galnt6 10432661 7,34 0,18 5,78 0,21 1,56071 3,16E-05
Plp1 10601888 13,41 0,11 11,86 0,3 1,54597 4,45E-05
Pllp 10580765 9,53 0,16 8,02 0,22 1,50080 2,45E-05
Car14 10500283 8,28 0,06 6,79 0,15 1,49057 2,10E-06
Erbb3 10373467 8,51 0,14 7,03 0,15 1,48027 8,22E-06
Sept4 10380067 10,42 0,15 8,95 0,17 1,46989 1,50E-05
Ttyh2 10382376 10,46 0,07 9,01 0,21 1,44890 9,76E-06
Mobp 10590269 11,65 0,12 10,22 0,47 1,43296 0,0005
Qdpr 10529895 11,25 0,13 9,81 0,27 1,43296 7,32E-05
Prr5l 10485378 7,55 0,09 6,12 0,32 1,42761 0,0001
Tmem63a 10352320 9,55 0,15 8,15 0,25 1,40054 4,21E-05
Nipal4 10385384 8,1 0,1 6,71 0,12 1,39506 2,27E-06
Plekhb1 10565910 11,95 0,05 10,58 0,25 1,37295 4,40E-05
Lpar1 10513256 9,66 0,12 8,29 0,12 1,36737 4,43E-06
Unc5b 10369388 8,7 0,1 7,36 0,19 1,34483 1,53E-05
Carns1 10464642 8,5 0,08 7,16 0,14 1,33914 6,89E-06
Plxnb3 10600249 9,02 0,1 7,69 0,05 1,32769 2,05E-06
Il33 10462442 9,41 0,21 8,09 0,34 1,31615 0,0005
Gjb1 10601161 7,61 0,24 6,35 0,32 1,26903 0,0004
Cntn2 10357705 9,96 0,07 8,7 0,1 1,26303 2,10E-06
Phldb1 10592891 9,6 0,17 8,35 0,1 1,24489 1,50E-05
Mbp 10457022 12,22 0,08 10,99 0,22 1,23266 3,56E-05
Cpm 10366546 8,32 0,13 7,11 0,25 1,20789 0,0001
Prr18 10441657 8,52 0,15 7,31 0,07 1,20789 8,22E-06
Efnb3 10387483 9,59 0,17 8,41 0,13 1,17632 2,99E-05
Smco3 10548871 8,3 0,07 7,12 0,32 1,17632 0,0001
Gsn 10471655 8,91 0,19 7,75 0,1 1,15704 4,07E-05
Mob3b 10512022 8,58 0,1 7,43 0,21 1,15056 5,80E-05
Pigz 10434993 9,21 0,12 8,06 0,18 1,14405 4,25E-05
Ccp110 10556640 9,58 0,06 8,44 0,04 1,13750 2,05E-06
Pde8a 10554521 8,94 0,18 7,8 0,1 1,13750 2,99E-05
Gm22290 10416897 4,27 0,54 3,15 0,37 1,11770 0,0302
Lrrn1 10540401 10,68 0,08 9,59 0,07 1,09761 3,77E-06
Apln 10604375 9,08 0,05 8 0,28 1,08406 0,0005
Myrf 10465916 9,6 0,1 8,52 0,28 1,07724 0,0004
D7Ertd443e 10568696 7,8 0,11 6,74 0,21 1,05658 0,0001
Fam57a 10378754 9,78 0,08 8,72 0,1 1,05658 1,26E-05
Ptgds 10480734 11,25 0,12 10,19 0,46 1,05658 0,0062
Cers2 10494227 10,22 0,15 9,17 0,2 1,04963 0,0002
Cd82 10485213 9,65 0,24 8,62 0,26 1,03562 0,0009
Cryab 10585214 11,59 0,09 10,56 0,16 1,03562 4,40E-05
Elovl7 10407072 9,14 0,18 8,11 0,19 1,03562 0,0002
Prrg1 10605493 7,53 0,1 6,5 0,08 1,02857 8,22E-06
Enpp2 10428619 11,75 0,28 10,74 0,57 1,00000 0,0252
Rhog 10566132 9,61 0,1 8,61 0,16 1,00000 9,84E-05
Gjc3 10534960 11,15 0,07 10,16 0,3 0,99277 0,0007
Sgk2 10478326 7,22 0,13 6,23 0,29 0,99277 0,0005
Gstm7 10501199 9,23 0,16 8,24 0,19 0,98550 0,0002
Mboat1 10404359 7,42 0,18 6,43 0,11 0,98550 6,44E-05
Mcam 10584674 9,25 0,07 8,27 0,13 0,97820 2,62E-05
Evi2a; Evi2b; Gm21975 10388958 8,41 0,14 7,43 0,21 0,97085 0,0004
Map6d1 10438456 10,26 0,06 9,3 0,03 0,97085 4,00E-06
Slc12a2 10455873 10,15 0,17 9,18 0,23 0,97085 0,0006
Plekhg3 10396671 8,1 0,19 7,13 0,18 0,96347 0,0006
Scd1 10467979 11,33 0,07 10,37 0,19 0,96347 9,84E-05
Tprn 10469957 7,82 0,06 6,85 0,12 0,96347 2,03E-05
Dock5 10421046 8,49 0,14 7,53 0,16 0,95606 0,0001
Trim59 10498620 7,88 0,25 6,92 0,33 0,95606 0,0043
Lgi3 10416279 10,97 0,12 10,02 0,23 0,94111 0,0002
Sh3gl3 10554588 9,3 0,15 8,37 0,13 0,93357 0,0002
Tppp3 10581266 9,87 0,15 8,93 0,18 0,93357 0,0003
Josd2 10552681 9,62 0,11 8,7 0,11 0,91839 6,40E-05
Tmem98 10379489 7,93 0,16 7,02 0,18 0,91839 0,0001
Hhip 10579894 8,33 0,18 7,42 0,16 0,91073 0,0003
Desi1 10430804 11,28 0,08 10,37 0,1 0,90304 2,81E-05
Trim13 10415784 9,32 0,1 8,42 0,08 0,90304 3,53E-05
Gjc2 10386352 7,93 0,09 7,04 0,09 0,89530 2,45E-05
Gm10863 10425265 7,84 0,18 6,95 0,04 0,89530 0,0001
Gm38481; Idi1 10482762 9,79 0,12 8,9 0,11 0,89530 6,42E-05
Idi1 10403413 10,02 0,15 9,13 0,11 0,88753 0,0001
Pacs2 10398936 10,29 0,08 9,4 0,17 0,88753 0,0002
Prkcq 10469255 8,68 0,14 7,79 0,12 0,88753 6,42E-05
Elovl1 10507539 9,67 0,15 8,8 0,18 0,87184 0,0011
Olfml1 10556076 7,91 0,15 7,05 0,23 0,86394 0,0004
Slc7a10 10552143 9,46 0,07 8,59 0,28 0,86394 0,0019
St18 10344679 8,06 0,23 7,19 0,32 0,86394 0,0022
Abca2 10470050 10,63 0,06 9,79 0,12 0,84800 4,08E-05
Ebp 10603485 8,73 0,06 7,88 0,13 0,84800 4,45E-05
Gatm 10487011 11,89 0,13 11,04 0,25 0,84800 0,0009
Bche 10498710 6,83 0,07 5,99 0,19 0,83996 0,0002
Cdc42ep2 10465278 8,85 0,11 8 0,09 0,83996 5,55E-05
Sytl2 10554863 9,51 0,08 8,67 0,04 0,83996 1,50E-05
Abca8a 10392522 5,94 0,11 5,11 0,18 0,83188 0,0003
Pla2g16 10461093 8,24 0,17 7,42 0,24 0,83188 0,0021
Sec14l5 10433373 7,61 0,13 6,78 0,24 0,83188 0,0009
Srd5a1 10410452 8,3 0,09 7,48 0,06 0,82375 2,99E-05
Dbndd2 10478495 8,73 0,08 7,92 0,13 0,81558 8,91E-05
Gm9791 10497752 9,38 0,14 8,57 0,1 0,81558 0,0003
Ctnna3 10363676 6,81 0,09 6 0,2 0,80735 0,0005
Mfge8 10564713 9,61 0,07 8,8 0,13 0,80735 6,44E-05
Mir219a-2; Gm3088 10481378 7,38 0,14 6,57 0,13 0,80735 0,0007
Rtkn2 10363743 6,65 0,1 5,85 0,09 0,80735 6,42E-05
Shtn1 10468762 9,23 0,09 8,42 0,15 0,80735 0,0001
Nmral1 10437432 7,71 0,18 6,91 0,06 0,79909 0,0003
Ano4 10371740 8,79 0,09 7,99 0,1 0,79077 6,42E-05
Rffl 10389087 8,42 0,02 7,63 0,12 0,79077 4,40E-05
Ldlr 10583732 8,76 0,13 7,98 0,08 0,78241 0,0002
Pls1 10595768 8,24 0,07 7,46 0,22 0,78241 0,0007
Arhgap23 10380773 9,37 0,11 8,59 0,03 0,77400 5,15E-05
Car2 10490923 11,35 0,14 10,58 0,28 0,77400 0,0074
Gng8 10550388 6,81 0,11 6,03 0,1 0,77400 0,0002
Mir100 10584589 6,24 0,19 5,47 0,3 0,77400 0,0077
Ankub1 10498302 7,44 0,13 6,67 0,36 0,76553 0,0041
Apod 10439009 12,02 0,07 11,26 0,16 0,76553 0,0004
Clmn 10402473 9,33 0,13 8,57 0,37 0,76553 0,0383
Insig1 10520362 9,88 0,24 9,12 0,18 0,76553 0,0017
Map7 10361956 9,63 0,07 8,87 0,08 0,76553 4,21E-05
Gstm5 10495243 10,05 0,19 9,3 0,1 0,75702 0,0009
Adssl1 10398859 8,54 0,21 7,79 0,2 0,74846 0,0014
Bcas1 10490061 10,21 0,15 9,46 0,21 0,74846 0,0016
Gm9895 10462343 6,94 0,22 6,19 0,16 0,74846 0,0019
Hmgcs1 10412466 10,5 0,11 9,75 0,06 0,74846 8,44E-05
Kctd4 10416505 7,52 0,17 6,77 0,18 0,74846 0,0007
Lrp4 10473880 8,81 0,13 8,07 0,05 0,74846 0,0001
Myo1d 10389022 8,87 0,15 8,12 0,2 0,74846 0,0013
Slc44a1 10505008 10,67 0,11 9,92 0,04 0,74846 9,84E-05
Enpp6 10571715 8,46 0,08 7,72 0,1 0,73985 9,84E-05
Sp7 10433003 6,55 0,24 5,81 0,2 0,73985 0,0025
Usp54 10417920 9,37 0,11 8,63 0,16 0,73985 0,0006
Chil1 10349968 7,81 0,15 7,07 0,37 0,73118 0,0147
Gpr37 10543466 9,87 0,18 9,15 0,38 0,73118 0,0066
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